Amedeo Smart

Free Medical Literature Service


 

Amedeo

Influenza

  Free Subscription

Articles published in
Vaccine
    September 2021
  1. PALACHE A, Rockman S, Taylor B, Akcay M, et al
    Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use.
    Vaccine. 2021 Sep 11. pii: S0264-410X(21)01157.
    >> Share

  2. THOMPSON MG, Soto G, Perez A, Newes-Adeyim G, et al
    Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019.
    Vaccine. 2021 Sep 8. pii: S0264-410X(21)00982.
    >> Share

  3. JOGI P, Soeorg H, Ingerainen D, Soots M, et al
    Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study).
    Vaccine. 2021;39:5376-5384.
    >> Share

    August 2021
  4. PRIVOR-DUMM LA, Poland GA, Barratt J, Durrheim DN, et al
    A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
    Vaccine. 2021;39:5240-5250.
    >> Share

  5. CANTARELLI P, Belle N, Quattrone F
    Nudging influenza vaccination among health care workers.
    Vaccine. 2021 Aug 31. pii: S0264-410X(21)01073.
    >> Share

  6. O'LORCAIN P, Cotter S, Walsh C
    Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020).
    Vaccine. 2021 Aug 27. pii: S0264-410X(21)00987.
    >> Share

  7. PIERCE-RUIZ C, Santana WI, Sutton WJH, Fischler DA, et al
    Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry.
    Vaccine. 2021;39:5106-5115.
    >> Share

  8. WIEMKEN TL, Salas J, Hoft DF, Jacobs C, et al
    Dementia risk following influenza vaccination in a large veteran cohort running head: Influenza vaccination and dementia.
    Vaccine. 2021 Aug 19. pii: S0264-410X(21)01079.
    >> Share

  9. PENG HK, Dombkowski KJ, Freed GL, Creary SE, et al
    Influenza immunization coverage of children with sickle cell disease.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01072.
    >> Share

  10. LAUFER RS, Driscoll AJ, Baral R, Buchwald AG, et al
    Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions.
    Vaccine. 2021;39:5037-5045.
    >> Share

  11. PALLADINO G, Ferrari A, Music N, Settembre EC, et al
    Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine.
    Vaccine. 2021 Aug 12. pii: S0264-410X(21)01041.
    >> Share

  12. STINSON JA, Boopathy AV, Cieslewicz BM, Zhang Y, et al
    Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)00957.
    >> Share

  13. GRUPEL D, Gazit S, Schreiber L, Nadler V, et al
    Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.
    Vaccine. 2021 Aug 11. pii: S0264-410X(21)01045.
    >> Share

  14. PETRIE JG, Fligiel H, Lamerato L, Martin ET, et al
    Agreement between state registry, health record, and self-report of influenza vaccination.
    Vaccine. 2021 Aug 9. pii: S0264-410X(21)00995.
    >> Share

  15. LYTLE KL, Collins SP, Feldstein LR, Baughman AH, et al
    Influenza vaccine acceptance and hesitancy among adults hospitalized with severe acute respiratory illnesses, United States 2019-2020.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00948.
    >> Share

  16. YOSHIKAWA T
    Implementing vaccination policies based upon scientific evidence in Japan.
    Vaccine. 2021 Aug 7. pii: S0264-410X(21)00968.
    >> Share

  17. FENG J, Li Q
    How to ensure vaccine safety: An evaluation of China's vaccine regulation system.
    Vaccine. 2021 Aug 6. pii: S0264-410X(21)00986.
    >> Share

  18. D'SOUZA MP, Palin AC, Calder T, Golding H, et al
    Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases.
    Vaccine. 2021 Aug 5. pii: S0264-410X(21)00964.
    >> Share

  19. HAUPT RE, Harberts EM, Kitz RJ, Strohmeier S, et al
    Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00847.
    >> Share

  20. SAKALA IG, Honda-Okubo Y, Li L, Baldwin J, et al
    A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00914.
    >> Share

  21. HAYMAN B, Dennehy M
    Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Vaccine. 2021 Aug 3. pii: S0264-410X(21)00922.
    >> Share

    July 2021
  22. REDONDO E, Drago G, Lopez-Belmonte JL, Guillen JM, et al
    Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00926.
    >> Share

  23. KONTOPOULOU K, Ainatzoglou A, Nakas CT, Ifantidou A, et al
    Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00958.
    >> Share

  24. SIDDIQUI A, Ahmed A, Tanveer M, Saqlain M, et al
    An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00965.
    >> Share

  25. MAHAJAN A, Kaur J, Sidana C, Shivam S, et al
    Geo-prioritization framework for COVID-19 vaccine allocation in India.
    Vaccine. 2021 Jul 31. pii: S0264-410X(21)00989.
    >> Share

  26. RAGHUNANDAN R, Higgins D, Hosken N
    RSV neutralization assays - Use in immune response assessment.
    Vaccine. 2021;39:4591-4597.
    >> Share

  27. DIACO M, Yin K, Seet B, Samson S, et al
    Author response to a Letter to the Editor on "Introductory paper: High dose influenza vaccine".
    Vaccine. 2021 Jul 28. pii: S0264-410X(21)00917.
    >> Share

  28. YU VG, Lasco G, David CC
    Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00929.
    >> Share

  29. GEORGIADIS GP, Georgiadis MC
    Optimal planning of the COVID-19 vaccine supply chain.
    Vaccine. 2021 Jul 27. pii: S0264-410X(21)00961.
    >> Share

  30. RAJAN S, Akhtar N, Sharma S, Chakrabarti D, et al
    COVID-19 vaccination for cancer patients: Evidence, priority, and practice.
    Vaccine. 2021 Jul 24. pii: S0264-410X(21)00956.
    >> Share

  31. CALLAHAN AG, Coleman-Cowger VH, Schulkin J, Power ML, et al
    Racial disparities in influenza immunization during pregnancy in the United States: A narrative review of the evidence for disparities and potential interventions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00905.
    >> Share

  32. BURKE PF, Masters D, Massey G
    Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00947.
    >> Share

  33. TEASDALE CA, Borrell LN, Shen Y, Kimball S, et al
    Parental plans to vaccinate children for COVID-19 in New York city.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00949.
    >> Share

  34. SUNDARAM M, Nasreen S, Calzavara A, He S, et al
    Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments.
    Vaccine. 2021 Jul 23. pii: S0264-410X(21)00951.
    >> Share

  35. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    >> Share

  36. ARIAS-FERNANDEZ L, San-Roman Montero J, Gil-Prieto R, Walter S, et al
    Burden of pneumonia in patients with viral and bacterial coinfection in Spain during six consecutive influenza seasons, from 2009-10 to 2014-15.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00912.
    >> Share

  37. HERVE PL, Dhelft V, Zuniga A, Ghasparian A, et al
    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Vaccine. 2021;39:4555-4563.
    >> Share

  38. MATHIVATHANAN K
    Will COVID-19 vaccine equity be possible in India?
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00927.
    >> Share

  39. TISSOT N, Brunel AS, Bozon F, Rosolen B, et al
    Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine.
    Vaccine. 2021 Jul 22. pii: S0264-410X(21)00925.
    >> Share

  40. CHUA H, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00873.
    >> Share

  41. INGROLE RSJ, Tao W, Joshi G, Gill HS, et al
    M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00909.
    >> Share

  42. PAUL E, Brown GW, Kalk A, Ridde V, et al
    Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager.
    Vaccine. 2021 Jul 20. pii: S0264-410X(21)00923.
    >> Share

  43. FLUCKIGER AC, Ontsouka B, Bozic J, Diress A, et al
    An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00911.
    >> Share

  44. INSERRA F, Tajer C, Antonietti L, Mariani J, et al
    Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00908.
    >> Share

  45. JAIN R, Chopra A, Falezan C, Patel M, et al
    COVID-19 related immunization disruptions in Rajasthan, India: A retrospective observational study.
    Vaccine. 2021;39:4343-4350.
    >> Share

  46. PICHE-RENAUD PP, Ji C, Farrar DS, Friedman JN, et al
    Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada.
    Vaccine. 2021;39:4373-4382.
    >> Share

  47. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    >> Share

  48. HAYMAN B, Suri R, Prasad SD
    COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspective.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00866.
    >> Share

  49. LAZAROS G, Klein AL, Hatziantoniou S, Tsioufis C, et al
    The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00875.
    >> Share

  50. CLARKE M, Goodchild LM, Evans S, Giles LC, et al
    Body mass index and vaccine responses following influenza vaccination during pregnancy.
    Vaccine. 2021 Jul 12. pii: S0264-410X(21)00826.
    >> Share

  51. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    >> Share

  52. MATEO-URDIALES A, Del Manso M, Andrianou X, Spuri M, et al
    Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
    Vaccine. 2021 Jul 7. pii: S0264-410X(21)00862.
    >> Share

  53. BELLIER L, Petitjean A, Sarazu T, Tresierra J, et al
    Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Vaccine. 2021;39:4144-4152.
    >> Share

  54. LO CY, Misplon JA, Li X, Price GE, et al
    Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00833.
    >> Share

  55. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    >> Share

    June 2021
  56. HINES AM, Murphy N, Mullin C, Barillas J, et al
    Henoch-Schonlein purpura presenting post COVID-19 vaccination.
    Vaccine. 2021 Jun 30. pii: S0264-410X(21)00841.
    >> Share

  57. YOUSSEF Y, Chmaisse A, Boutros C, Chamseddine S, et al
    The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review.
    Vaccine. 2021;39:3803-3813.
    >> Share

  58. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    >> Share

  59. BANKS C, Portnoy A, Moi F, Boonstoppel L, et al
    Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00838.
    >> Share

  60. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    >> Share

  61. MYLES IA, Vinciguerra JS, Premus RT
    Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
    Vaccine. 2021 Jun 25. pii: S0264-410X(21)00811.
    >> Share

  62. GUAN L, Yu Y, Wu X, Nie J, et al
    The first Chinese national standards for SARS-CoV-2 neutralizing antibody.
    Vaccine. 2021;39:3724-3730.
    >> Share

  63. DESAI AP, Desai AP, Loomis GJ
    Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00808.
    >> Share

  64. BALDOLLI A, Michon J, Appia F, Galimard C, et al
    Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00804.
    >> Share

  65. GOOCH KE, Smith TRF, Salguero FJ, Fotheringham SA, et al
    One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00807.
    >> Share

  66. CHEN IH, Ahorsu DK, Ko NY, Yen CF, et al
    Adapting the Motors of Influenza Vaccination Acceptance Scale into the Motors of COVID-19 Vaccination Acceptance Scale: Psychometric evaluation among mainland Chinese university students.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00794.
    >> Share

  67. LUNDBERG L, Bygdell M, Stukat von Feilitzen G, Woxenius S, et al
    Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study.
    Vaccine. 2021 Jun 22. pii: S0264-410X(21)00795.
    >> Share

  68. SMITH KJ, Wateska AR, Nowalk MP, Lin CJ, et al
    Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
    Vaccine. 2021 Jun 21. pii: S0264-410X(21)00773.
    >> Share

  69. FOGEL B, Schaefer EW, Hicks SD
    Early influenza vaccination rates decline in children during the COVID-19 pandemic.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00777.
    >> Share

  70. BROWN CC, Young SG, Pro GC
    COVID-19 vaccination rates vary by community vulnerability: A county-level analysis.
    Vaccine. 2021 Jun 17. pii: S0264-410X(21)00774.
    >> Share

  71. BIFULCO M, Pisanti S, Fusco I
    Lessons from the 1656 Neapolitan Plague: Something to learn for the current coronavirus Pandemic?
    Vaccine. 2021;39:3641-3643.
    >> Share

  72. JETHWA H, Wong R, Abraham S
    Covid-19 vaccine trials: Ethnic diversity and immunogenicity.
    Vaccine. 2021;39:3541-3543.
    >> Share

  73. PRASAD N, Read JM, Jewell C, Waite B, et al
    Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Vaccine. 2021 Jun 16. pii: S0264-410X(21)00708.
    >> Share

  74. ZIMMERMAN RK
    Helping patients with ethical concerns about COVID-19 vaccines in light of fetal cell lines used in some COVID-19 vaccines.
    Vaccine. 2021 Jun 15. pii: S0264-410X(21)00763.
    >> Share

  75. POLAND GA, Ovsyannikova IG, Kennedy RB
    The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00764.
    >> Share

  76. IVANOV V, Oomens AGP, Papin JF, Staats R, et al
    Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Vaccine. 2021 Jun 14. pii: S0264-410X(21)00737.
    >> Share

  77. FERRARI D, Di Resta C, Tomaiuolo R, Sabetta E, et al
    Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00756.
    >> Share

  78. LIPSITCH M, Kahn R
    Interpreting vaccine efficacy trial results for infection and transmission.
    Vaccine. 2021 Jun 12. pii: S0264-410X(21)00735.
    >> Share

  79. MCFADDEN K, Heywood A, Dyda A, Kaufman J, et al
    Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?
    Vaccine. 2021;39:3467-3472.
    >> Share

  80. BEAU RENEER Z, Abreu RB, Jamal US, Corn MR, et al
    Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00659.
    >> Share

  81. HSIA J, Zhao G, Lu PJ, Town M, et al
    Estimating bias from internet non-use for a hybrid web vaccination survey - 2013-2017 Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00675.
    >> Share

  82. LUTZ CS, Biggerstaff M, Rolfes MA, Lafond KE, et al
    Estimating the number of averted illnesses and deaths as a result of vaccination against an influenza pandemic in nine low- and middle-income countries.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00557.
    >> Share

  83. GUNTUKU SC, Buttenheim AM, Sherman G, Merchant RM, et al
    Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States.
    Vaccine. 2021 Jun 9. pii: S0264-410X(21)00738.
    >> Share

  84. IKILEZI G, Bachmeier SD, Cogswell IE, Maddison ER, et al
    Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data.
    Vaccine. 2021;39:3410-3418.
    >> Share

  85. NUZHATH T, Ajayi KV, Fan Q, Hotez P, et al
    Childhood immunization during the COVID-19 pandemic in Texas.
    Vaccine. 2021;39:3333-3337.
    >> Share

  86. SILVEIRA MF, Tonial CT, Goretti K Maranhao A, Teixeira AMS, et al
    Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey.
    Vaccine. 2021;39:3404-3409.
    >> Share

  87. JENSEN A, A F Simoes E, Bohn Christiansen C, Graff Stensballe L, et al
    Respiratory syncytial virus and influenza hospitalizations in Danish children 2010-2016.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00705.
    >> Share

  88. HOEHL S, Ciesek S, Graf J, Wicker S, et al
    A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated.
    Vaccine. 2021 Jun 8. pii: S0264-410X(21)00736.
    >> Share

  89. ANDAYI F, Emukule GO, Osoro E, Ndegwa LK, et al
    Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemic.
    Vaccine. 2021 Jun 7. pii: S0264-410X(21)00643.
    >> Share

  90. RAZ A, Keshet Y, Popper-Giveon A, Karkabi MS, et al
    One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy.
    Vaccine. 2021 Jun 5. pii: S0264-410X(21)00714.
    >> Share

  91. DAL-RE R, Launay O
    Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label.
    Vaccine. 2021 Jun 4. pii: S0264-410X(21)00703.
    >> Share

  92. STUURMAN AL, Biccler J, Carmona A, Descamps A, et al
    Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00654.
    >> Share

  93. GATES A, Rahman S, Sim S, Pillay J, et al
    Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00640.
    >> Share

  94. FERDINANDS JM, Thompson MG, Blanton L, Spencer S, et al
    Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00562.
    >> Share

  95. SHINGAI M, Nomura N, Sekiya T, Ohno M, et al
    Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00660.
    >> Share

  96. LASKY T, McMahon AW, Hua W, Forshee R, et al
    Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review.
    Vaccine. 2021 Jun 2. pii: S0264-410X(21)00666.
    >> Share

  97. WANG Y, Zhang Y, Wu H, Huang L, et al
    Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00665.
    >> Share

  98. DEY A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, et al
    Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00706.
    >> Share

  99. PATEL MK, Bergeri I, Bresee JS, Cowling BJ, et al
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
    Vaccine. 2021 Jun 1. pii: S0264-410X(21)00707.
    >> Share

    May 2021
  100. ZIPFEL CM, Colizza V, Bansal S
    The missing season: The impacts of the COVID-19 pandemic on influenza.
    Vaccine. 2021 May 30. pii: S0264-410X(21)00635.
    >> Share

  101. LEWIS NS, Banyard AC, Essen S, Whittard E, et al
    Antigenic evolution of contemporary clade 2.3.4.4 HPAI H5 influenza A viruses and impact on vaccine use for mitigation and control.
    Vaccine. 2021 May 29. pii: S0264-410X(21)00655.
    >> Share

  102. BARDENHEIER BH, Gravenstein S, Blackman C, Gutman R, et al
    Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00683.
    >> Share

  103. ABU MOUCH S, Roguin A, Hellou E, Ishai A, et al
    Myocarditis following COVID-19 mRNA vaccination.
    Vaccine. 2021 May 28. pii: S0264-410X(21)00682.
    >> Share

  104. GURWITZ D
    COVID-19 vaccine hesitancy: Lessons from Israel.
    Vaccine. 2021 May 27. pii: S0264-410X(21)00680.
    >> Share

  105. KESSELS R, Luyten J, Tubeuf S
    Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
    Vaccine. 2021 May 26. pii: S0264-410X(21)00664.
    >> Share

  106. VANHEMS P
    A breath of humanity in the era of Covid-19 vaccine.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00638.
    >> Share

  107. EARLE KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, et al
    Evidence for antibody as a protective correlate for COVID-19 vaccines.
    Vaccine. 2021 May 24. pii: S0264-410X(21)00658.
    >> Share

  108. SAM IC, Ahmad Jaafar N, Wong LP, Nathan AM, et al
    Socioeconomic costs of children <5 years hospitalised with acute respiratory infections in Kuala Lumpur, Malaysia.
    Vaccine. 2021;39:2983-2988.
    >> Share

  109. VOGEL TP, Top KA, Karatzios C, Hilmers DC, et al
    Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3037-3049.
    >> Share

  110. SERAZIN NA, Edem B, Williams SR, Ortiz JR, et al
    Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021;39:3028-3036.
    >> Share

  111. AIZAWA Y, Katsuta T, Sakiyama H, Tanaka-Taya K, et al
    Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan.
    Vaccine. 2021 May 21. pii: S0264-410X(21)00636.
    >> Share

  112. NICHOLLS LAB, Gallant AJ, Cogan N, Rasmussen S, et al
    Older adults' vaccine hesitancy: Psychosocial factors associated with influenza, pneumococcal, and shingles vaccine uptake.
    Vaccine. 2021 May 19. pii: S0264-410X(21)00544.
    >> Share

  113. KIM S, Williams TC, Viboud C, Campbell H, et al
    RSV genomic diversity and the development of a globally effective RSV intervention.
    Vaccine. 2021;39:2811-2820.
    >> Share

  114. NAG K, Chandra Baray J, Rahman Khan M, Mahmud A, et al
    An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00607.
    >> Share

  115. LUK TT, Zhao S, Wu Y, Wong JY, et al
    Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey.
    Vaccine. 2021 May 18. pii: S0264-410X(21)00608.
    >> Share

  116. CHAN YW, Wong ML, Kwok FY, Au AK, et al
    The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20.
    Vaccine. 2021 May 17. pii: S0264-410X(21)00541.
    >> Share

  117. GUBERNOT D, Jazwa A, Niu M, Baumblatt J, et al
    U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00578.
    >> Share

  118. WOOD RM, Murch BJ, Moss SJ, Tyler JMB, et al
    Operational research for the safe and effective design of COVID-19 mass vaccination centres.
    Vaccine. 2021 May 14. pii: S0264-410X(21)00588.
    >> Share

  119. CHUNG JR, Flannery B, Kim SS, Gaglani M, et al
    Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.
    Vaccine. 2021 May 13. pii: S0264-410X(21)00555.
    >> Share

  120. KIM TH, Choi JH, Park SH, Yoo JH, et al
    Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged >/= 65 years.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00551.
    >> Share

  121. KRAIGSLEY AM, Moore KA, Bolster A, Peters M, et al
    Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00502.
    >> Share

  122. AFIFI TO, Salmon S, Taillieu T, Stewart-Tufescu A, et al
    Older adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for informing public health strategies.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00590.
    >> Share

  123. LONGCHAMPS C, Ducarroz S, Crouzet L, Vignier N, et al
    COVID-19 vaccine hesitancy among persons living in homeless shelters in France.
    Vaccine. 2021 May 12. pii: S0264-410X(21)00563.
    >> Share

  124. LEUNG VKY, Fox A, Carolan LA, Aban M, et al
    Impact of prior vaccination on antibody response and influenza-like illness among Australian healthcare workers after influenza vaccination in 2016.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00483.
    >> Share

  125. POWELL H, Liu H, Pekosz A
    Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures.
    Vaccine. 2021 May 10. pii: S0264-410X(21)00535.
    >> Share

  126. PASTORINO R, Villani L, La Milia DI, Ieraci R, et al
    Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
    Vaccine. 2021 May 9. pii: S0264-410X(21)00566.
    >> Share

  127. HUANG JM, Wang SY, Lai MR, Tseng YK, et al
    Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
    Vaccine. 2021 May 7. pii: S0264-410X(21)00485.
    >> Share

  128. CORREIA R, Meneses L, Richheimer C, Alves PM, et al
    Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00480.
    >> Share

  129. SOMIYA M, Mine S, Yasukawa K, Ikeda S, et al
    Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines.
    Vaccine. 2021 May 6. pii: S0264-410X(21)00548.
    >> Share

    April 2021
  130. EYAL N, Gerhard T, Strom BL
    Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00526.
    >> Share

  131. WELSH KJ, Baumblatt J, Chege W, Goud R, et al
    Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Vaccine. 2021 Apr 30. pii: S0264-410X(21)00524.
    >> Share

  132. KINI A, Morgan R, Kuo H, Shea P, et al
    Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race.
    Vaccine. 2021 Apr 28. pii: S0264-410X(21)00448.
    >> Share

  133. SAITOH A, Okabe N
    Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00460.
    >> Share

  134. KWON JH, Criado MF, Killmaster L, Ali MZ, et al
    Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh.
    Vaccine. 2021 Apr 25. pii: S0264-410X(21)00459.
    >> Share

  135. KREPS SE, Kriner DL
    Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment.
    Vaccine. 2021 Apr 24. pii: S0264-410X(21)00503.
    >> Share

  136. OLATUNJI EA, Ogunsola AS, Khodakarami N, Callaghan T, et al
    Who receives influenza vaccinations at the Pharmacy? An analysis of the Texas Behavioral Risk Factor Surveillance System.
    Vaccine. 2021 Apr 22. pii: S0264-410X(21)00451.
    >> Share

  137. DADARI I, Higgins-Steele A, Sharkey A, Charlet D, et al
    Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
    Vaccine. 2021;39:2434-2444.
    >> Share

  138. WANG C, Han B, Zhao T, Liu H, et al
    Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00455.
    >> Share

  139. LEVIN Y, Balakirski NM, Caraco Y, Ben-Ami E, et al
    Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience.
    Vaccine. 2021 Apr 13. pii: S0264-410X(21)00452.
    >> Share

  140. HAMILTON RA, Krockow EM, Vekria P
    Attitudes towards influenza and uptake of the flu vaccine: A survey of pharmacy staff working in English hospitals.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00407.
    >> Share

  141. PU J, Yu Q, Yin Z, Zhang Y, et al
    The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00431.
    >> Share

  142. POLUEKTOV Y, George M, Daftarian P, Delcommenne MC, et al
    Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Vaccine. 2021;39:2110-2116.
    >> Share

  143. HOGAN AB, Winskill P, Watson OJ, Walker PGT, et al
    Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00427.
    >> Share

  144. PAGLIUSI S, Hayman B, Jarrett S
    Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Vaccine. 2021 Apr 7. pii: S0264-410X(21)00293.
    >> Share

  145. DANIELS V, Saxena K, Roberts C, Kothari S, et al
    Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00428.
    >> Share

  146. GRAMACHO WG, Turgeon M
    When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00396.
    >> Share

  147. HATZIANTONIOU S, Maltezou HC, Tsakris A, Poland GA, et al
    Anaphylactic reactions to mRNA COVID-19 vaccines: A call for further study.
    Vaccine. 2021 Apr 6. pii: S0264-410X(21)00377.
    >> Share

    March 2021
  148. PELTON SI, Divino V, Postma MJ, Shah D, et al
    A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Vaccine. 2021 Mar 30. pii: S0264-410X(21)00347.
    >> Share

  149. GUR-ARIE R, Katz MA, Hirsch A, Greenberg D, et al
    "You Have to Die Not to Come to Work": A Mixed Methods Study of Attitudes and Behaviors regarding Presenteeism, Absenteeism and Influenza Vaccination among Healthcare Personnel with Respiratory Illness in Israel, 2016-2019.
    Vaccine. 2021 Mar 29. pii: S0264-410X(21)00361.
    >> Share

  150. KUTER BJ, Offit PA, Poland GA
    The development of COVID-19 vaccines in the United States: Why and how so fast?
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00383.
    >> Share

  151. RUSSO AG, Decarli A, Valsecchi MG
    Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study.
    Vaccine. 2021 Mar 26. pii: S0264-410X(21)00382.
    >> Share

  152. GKENTZI D, Aggelopoulos K, Karatza A, Sinopidis X, et al
    Influenza vaccination among caregivers and household contacts of children with asthma.
    Vaccine. 2021 Mar 25. pii: S0264-410X(21)00325.
    >> Share

  153. SALMON DA, Dudley MZ, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization.
    Vaccine. 2021 Mar 24. pii: S0264-410X(21)00315.
    >> Share

  154. ROSA SS, Prazeres DMF, Azevedo AM, Marques MPC, et al
    mRNA vaccines manufacturing: Challenges and bottlenecks.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00319.
    >> Share

  155. HAEDER SF
    Joining the herd? U.S. public opinion and vaccination requirements across educational settings during the COVID-19 pandemic.
    Vaccine. 2021 Mar 23. pii: S0264-410X(21)00348.
    >> Share

  156. KOCHHAR S, Dube E, Graham J, Jee Y, et al
    COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER).
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00364.
    >> Share

  157. ZHANG Y, Li D, Zhao H, Wang L, et al
    The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00371.
    >> Share

  158. ANTONELLI INCALZI R, Trevisan C, Del Signore S, Volpato S, et al
    Are vaccines against COVID-19 tailored to the most vulnerable people?
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00370.
    >> Share

  159. ANGELIS A, Darrow J
    Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines.
    Vaccine. 2021 Mar 22. pii: S0264-410X(21)00346.
    >> Share

  160. KENDAL A
    Safety monitoring of COVID-19 vaccines - Lessons learned from the 1976 national influenza immunization program about detecting rare vaccine-related severe adverse events in emergency mass-vaccination programs.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00283.
    >> Share

  161. CHEN D, Ye Z, Pi Z, Mizukami S, et al
    Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00324.
    >> Share

  162. VILCHES TN, Zhang K, Van Exan R, Langley JM, et al
    Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada.
    Vaccine. 2021 Mar 20. pii: S0264-410X(21)00362.
    >> Share

  163. CAMBOU MC, Copeland TP, Nielsen-Saines K, Macinko J, et al
    Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00294.
    >> Share

  164. GRAUPENSPERGER S PHD, Abdallah DA, Lee CM
    Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00286.
    >> Share

  165. SZIGETI R, Kellermayer R
    Natural unblinding of BCG vaccination trials.
    Vaccine. 2021 Mar 17. pii: S0264-410X(21)00320.
    >> Share

  166. ALLINGTON D, McAndrew S, Moxham-Hall VL, Duffy B, et al
    Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK.
    Vaccine. 2021 Mar 16. pii: S0264-410X(21)00234.
    >> Share

  167. CHOI UY, Kim KH, Lee KY, Kim JH, et al
    Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.
    Vaccine. 2021 Mar 15. pii: S0264-410X(21)00273.
    >> Share

  168. NET P, Colrat F, Nascimento Costa M, Bianic F, et al
    Estimating public health and economic benefits along 10 years of Fluzone(R) High Dose in the United States.
    Vaccine. 2021;39 Suppl 1:A56-A69.
    >> Share

  169. BUTTERY JP
    Developing standard safety outcomes for COVID-19 vaccines.
    Vaccine. 2021 Mar 12. pii: S0264-410X(21)00272.
    >> Share

  170. LEE J, Li Y, Li Y, Cino-Ozuna AG, et al
    Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00268.
    >> Share

  171. BERTRAN K, Kassa A, Criado MF, Nunez IA, et al
    Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
    Vaccine. 2021 Mar 11. pii: S0264-410X(21)00266.
    >> Share

  172. EBAMA MS, Chu SY, Azziz-Baumgartner E, Lafond KE, et al
    Ancillary benefits of seasonal influenza vaccination in middle-income countries.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00228.
    >> Share

  173. LATKIN C, Dayton LA, Yi G, Konstantopoulos A, et al
    COVID-19 vaccine intentions in the United States, a social-ecological framework.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00238.
    >> Share

  174. REPERANT LA, Osterhaus ADME
    COVID-19 vaccination and critical care capacity: Perilous months ahead.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00316.
    >> Share

  175. WENTZELL E, Racila AM
    The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion.
    Vaccine. 2021 Mar 10. pii: S0264-410X(21)00317.
    >> Share

  176. GUIDRY JPD, Perrin PB, Laestadius LI, Vraga EK, et al
    U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.
    Vaccine. 2021 Mar 9. pii: S0264-410X(21)00306.
    >> Share

  177. SADARANGANI M, Abu Raya B, Conway JM, Iyaniwura SA, et al
    Importance of COVID-19 vaccine efficacy in older age groups.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00288.
    >> Share

  178. KISZEWSKI AE, Cleary EG, Jackson MJ, Ledley FD, et al
    NIH funding for vaccine readiness before the COVID-19 pandemic.
    Vaccine. 2021 Mar 8. pii: S0264-410X(21)00290.
    >> Share

  179. PULLAN S, Dey M
    Vaccine hesitancy and anti-vaccination in the time of COVID-19: A Google Trends analysis.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00287.
    >> Share

  180. BLACK SB, Law B, Chen RT, Dekker CL, et al
    The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety.
    Vaccine. 2021 Mar 6. pii: S0264-410X(21)00284.
    >> Share

  181. GASPAR EB, De Gaspari E
    Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
    Vaccine. 2021;39:1473-1475.
    >> Share

  182. YOKOMICHI H, Kojima R, Horiuchi S, Ooka T, et al
    Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00224.
    >> Share

  183. DU Y, Xu Y, Feng J, Hu L, et al
    Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Vaccine. 2021 Mar 5. pii: S0264-410X(21)00274.
    >> Share

  184. KUO H, Shapiro JR, Dhakal S, Morgan R, et al
    Sex-specific effects of age and body mass index on antibody responses to seasonal influenza vaccines in healthcare workers.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00227.
    >> Share

  185. WOO EJ, Moro PL
    Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00232.
    >> Share

  186. STURM L, Kasting ML, Head KJ, Hartsock JA, et al
    Influenza vaccination in the time of COVID-19: A national U.S. survey of adults.
    Vaccine. 2021 Mar 4. pii: S0264-410X(21)00271.
    >> Share

  187. HELMKAMP LJ, Szilagyi PG, Zimet G, Saville AW, et al
    A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines.
    Vaccine. 2021 Mar 3. pii: S0264-410X(21)00206.
    >> Share

  188. FELL DB, Dimitris MC, Hutcheon JA, Ortiz JR, et al
    Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.
    Vaccine. 2021 Mar 2. pii: S0264-410X(21)00261.
    >> Share

    February 2021
  189. WANG J, Lyu Y, Zhang H, Jing R, et al
    Willingness to pay and financing preferences for COVID-19 vaccination in China.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00240.
    >> Share

  190. SHEN M, Zu J, Fairley CK, Pagan JA, et al
    Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Vaccine. 2021 Feb 27. pii: S0264-410X(21)00236.
    >> Share

  191. SELL TK, Gastfriend D, Watson M, Watson C, et al
    Building the global vaccine manufacturing capacity needed to respond to pandemics.
    Vaccine. 2021 Feb 24. pii: S0264-410X(21)00165.
    >> Share

  192. MUNOZ FM, Cramer JP, Dekker CL, Dudley MZ, et al
    Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2021 Feb 23. pii: S0264-410X(21)00094.
    >> Share

  193. VERELST F, Beutels P, Hens N, Willem L, et al
    Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers' perspective.
    Vaccine. 2021 Feb 22. pii: S0264-410X(21)00168.
    >> Share

  194. SU QD, Zou YN, Yi Y, Shen LP, et al
    Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
    Vaccine. 2021;39:1241-1247.
    >> Share

  195. BLUNCK BN, Aideyan L, Ye X, Avadhanula V, et al
    A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.
    Vaccine. 2021;39:1248-1256.
    >> Share

  196. ELSENPETER HMS
    How COVID exposed the hypocrisy within me.
    Vaccine. 2021;39:1178-1179.
    >> Share

  197. ORTIZ JR, Robertson J, Hsu JS, Yu SL, et al
    The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region.
    Vaccine. 2021 Feb 19. pii: S0264-410X(21)00204.
    >> Share

  198. CHANG LJ, Anderson EJ, Jeanfreau R, He Y, et al
    Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6months through<18years of age: A randomized controlled phase II dose-finding trial.
    Vaccine. 2021 Feb 18. pii: S0264-410X(21)00162.
    >> Share

  199. KUTER BJ, Browne S, Momplaisir FM, Feemster KA, et al
    Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia.
    Vaccine. 2021 Feb 16. pii: S0264-410X(21)00185.
    >> Share

  200. WU MJ, Chung JR, Kim SS, Jackson ML, et al
    Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019.
    Vaccine. 2021 Feb 15. pii: S0264-410X(21)00106.
    >> Share

  201. GURWITZ D
    Ethical tradeoffs in SARS-CoV-2 vaccine development: Assuring fair availability for low-income countries.
    Vaccine. 2021;39:1027.
    >> Share

  202. RID A, Shah SK, Miller FG, Danis M, et al
    Ethical trade-offs in vaccine development and distribution-Response to Gurwitz.
    Vaccine. 2021;39:1028-1029.
    >> Share

  203. WARD BJ, Seguin A, Couillard J, Trepanier S, et al
    Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00004.
    >> Share

  204. POLAND CM, Matthews AKS, Poland GA
    Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design.
    Vaccine. 2021 Feb 10. pii: S0264-410X(21)00154.
    >> Share

  205. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Corrigendum to "Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance" [Vaccine 38(43) (2020) 6757-6765].
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00105.
    >> Share

  206. CHU L, McPhee R, Huang W, Bennett H, et al
    A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Vaccine. 2021 Feb 9. pii: S0264-410X(21)00153.
    >> Share

  207. ROBINSON E, Jones A, Lesser I, Daly M, et al
    International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples.
    Vaccine. 2021 Feb 6. pii: S0264-410X(21)00140.
    >> Share

  208. KUMAR N, Bhartiya S, Singh T
    Duration of anti-SARS-CoV-2 antibodies much shorter in India.
    Vaccine. 2021;39:886-888.
    >> Share

  209. DIACO M, Chang LJ, Seet B, Robertson CA, et al
    Introductory paper: High dose influenza vaccine.
    Vaccine. 2021 Feb 3. pii: S0264-410X(20)31147.
    >> Share

  210. WILCK MB, Jin Xu Z, Stek JE, Goveia MG, et al
    Protective immune responses against Haemophilus influenza type B elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS).
    Vaccine. 2021 Feb 1. pii: S0264-410X(21)00073.
    >> Share

    January 2021
  211. AXELSEN PH, Poland GA
    Vaccines, masks, distancing and credibility: An urgent warning for pandemic management.
    Vaccine. 2021 Jan 31. pii: S0264-410X(21)00079.
    >> Share

  212. COLRAT F, Thommes E, Largeron N, Alvarez FP, et al
    Economic evaluation of high-dose inactivated influenza vaccine in adults aged >/=65 years: A systematic literature review.
    Vaccine. 2021 Jan 29. pii: S0264-410X(20)31603.
    >> Share

  213. HAMPTON LM, Aggarwal R, Evans SJW, Law B, et al
    General determination of causation between Covid-19 vaccines and possible adverse events.
    Vaccine. 2021 Jan 29. pii: S0264-410X(21)00096.
    >> Share

  214. BERMAN L, Riedel M
    Coping with COVID.
    Vaccine. 2021;39:777-778.
    >> Share

  215. KIM SH, Paldurai A, Xiao S, Collins PL, et al
    Retraction notice to "Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens" [Vaccine 32(35) (2014) 4428-4435].
    Vaccine. 2021;39:775.
    >> Share

  216. WANG Y, Chen L, Cheng F, Biggerstaff M, et al
    Economic burden of influenza illness among children under 5 years in Suzhou, China: Report from the cost surveys during 2011/12 to 2016/17 influenza seasons.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31672.
    >> Share

  217. OKOLI GN, Racovitan F, Abdulwahid T, Righolt CH, et al
    Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studie
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00048.
    >> Share

  218. BHUIYAN MU, Stiboy E, Hassan MZ, Chan M, et al
    Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis.
    Vaccine. 2021;39:667-677.
    >> Share

  219. JAMROZIK E, Littler K, Bull S, Emerson C, et al
    Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Vaccine. 2021;39:633-640.
    >> Share

  220. BALASUBRAMANI GK, Zimmerman RK, Eng H, Lyons J, et al
    Comparison of local influenza vaccine effectiveness using two methods.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00017.
    >> Share

  221. DAL-RE R
    US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.
    Vaccine. 2021 Jan 20. pii: S0264-410X(21)00077.
    >> Share

  222. POLAND EG, McGuire DK, Ratishvili T, Poland GA, et al
    The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31694.
    >> Share

  223. WINOKUR P, El Sahly HM, Mulligan MJ, Frey SE, et al
    Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.
    Vaccine. 2021 Jan 20. pii: S0264-410X(20)31504.
    >> Share

  224. CAO L, Lou J, Zhao S, Chan RWY, et al
    In silico prediction of influenza vaccine effectiveness by sequence analysis.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00006.
    >> Share

  225. REEMERS S, Verstegen I, Basten S, Hubers W, et al
    A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.
    Vaccine. 2021 Jan 19. pii: S0264-410X(21)00022.
    >> Share

  226. FATOBA AJ, Maharaj L, Adeleke VT, Okpeku M, et al
    Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00003.
    >> Share

  227. SCOTT EM, Stein R, Brown MF, Hershberger J, et al
    Vaccination patterns of the northeast Ohio Amish revisited.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00026.
    >> Share

  228. WHITAKER JA, Parikh SA, Shanafelt TD, Kay NE, et al
    The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
    Vaccine. 2021 Jan 15. pii: S0264-410X(21)00001.
    >> Share

  229. GUALANO MR, Corradi A, Voglino G, Catozzi D, et al
    Healthcare Workers' (HCWs) attitudes towards mandatory influenza vaccination: A systematic review and meta-analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31655.
    >> Share

  230. AKMATOV MK, Holstiege J, Steffen A, Batzing J, et al
    Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis.
    Vaccine. 2021 Jan 12. pii: S0264-410X(20)31693.
    >> Share

  231. BURGER AE, Reither EN, Mamelund SE, Lim S, et al
    Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic.
    Vaccine. 2021 Jan 11. pii: S0264-410X(20)31666.
    >> Share

  232. WIEMKEN TL, Rutschman AS
    Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00018.
    >> Share

  233. SINGH J, Malik D, Raina A
    Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00015.
    >> Share

  234. RUIZ JB, Bell RA
    Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.
    Vaccine. 2021 Jan 9. pii: S0264-410X(21)00014.
    >> Share

  235. BEIGI RH, Krubiner C, Jamieson DJ, Lyerly AD, et al
    The need for inclusion of pregnant women in COVID-19 vaccine trials.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31671.
    >> Share

  236. GOLD MS, Lincoln G, Cashman P, Braunack-Mayer A, et al
    Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Vaccine. 2021;39:332-342.
    >> Share

  237. CALDERA F, Mercer M, Samson SI, Pitt JM, et al
    Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity.
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31490.
    >> Share

  238. WILLIAMS J, Degeling C, McVernon J, Dawson A, et al
    How should we conduct pandemic vaccination?
    Vaccine. 2021 Jan 7. pii: S0264-410X(20)31639.
    >> Share

  239. KELSO JM
    Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31696.
    >> Share

  240. KOHLI M, Maschio M, Becker D, Weinstein MC, et al
    The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31690.
    >> Share

  241. MIDDELDORP M, van Lier A, van der Maas N, Veldhuijzen I, et al
    Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31692.
    >> Share

  242. WONG MCS, Wong ELY, Huang J, Cheung AWL, et al
    Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31695.
    >> Share

  243. SU JR, McNeil MM, Welsh KJ, Marquez PL, et al
    Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.
    Vaccine. 2021 Jan 6. pii: S0264-410X(20)31614.
    >> Share

  244. GODINOT LD, Sicsic J, Lachatre M, Bouvet E, et al
    Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Vaccine. 2021 Jan 5. pii: S0264-410X(20)31637.
    >> Share

    December 2020
  245. JIANG X, Shang X, Lin J, Zhao Y, et al
    Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31608.
    >> Share

  246. DAMJANOVSKA S, Smith C, Sayin I, Burant CJ, et al
    Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines.
    Vaccine. 2020 Dec 31. pii: S0264-410X(20)31631.
    >> Share

  247. ZHONG Y, Clapham HE, Aishworiya R, Chua YX, et al
    Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore.
    Vaccine. 2020 Dec 26. pii: S0264-410X(20)31634.
    >> Share

  248. MORO PL, Marquez P
    Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31613.
    >> Share

  249. THANGARAJAH D, Malo JA, Field E, Andrews R, et al
    Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018.
    Vaccine. 2020 Dec 23. pii: S0264-410X(20)31579.
    >> Share

  250. MCFADDEN K, Seale H
    A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults.
    Vaccine. 2020 Dec 21. pii: S0264-410X(20)31610.
    >> Share

  251. SCHMIT T, Kuntz M, Patel D, Nadeem Khan M, et al
    Anti-capsular immunity to Streptococcus pneumoniae serotype 22F prevents bacterial transmission in murine colonization and influenza virus co-infection models.
    Vaccine. 2020 Dec 18. pii: S0264-410X(20)31558.
    >> Share

  252. SPARROW E, Wood JG, Chadwick C, Newall AT, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2019.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31585.
    >> Share

  253. FULVINI AA, Tuteja A, Le J, Pokorny BA, et al
    HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31563.
    >> Share

  254. BORRIELLO A, Master D, Pellegrini A, Rose JM, et al
    Preferences for a COVID-19 vaccine in Australia.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31599.
    >> Share

  255. BOKEMPER SE, Huber GA, Gerber AS, James EK, et al
    Timing of COVID-19 vaccine approval and endorsement by public figures.
    Vaccine. 2020 Dec 16. pii: S0264-410X(20)31616.
    >> Share

  256. SANFTENBERG L, Kuehne F, Anraad C, Jung-Sievers C, et al
    Assessing the impact of shared decision making processes on influenza vaccination rates in adult patients in outpatient care: A systematic review and meta-analysis.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31581.
    >> Share

  257. BROOCKMAN D, Kalla J, Guerrero A, Budolfson M, et al
    Broad cross-national public support for accelerated COVID-19 vaccine trial designs.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31555.
    >> Share

  258. BRAVO-GRANDE JL, Asuncion Blanco-Gonzalez M, de la Torre-Robles JM, Asmat-Inostrosa MP, et al
    Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
    Vaccine. 2020 Dec 14. pii: S0264-410X(20)31571.
    >> Share

  259. SARINHO E, Goudouris E, Sole D
    BCG vaccine: Worrying proposal for COVID-19.
    Vaccine. 2020 Dec 13. pii: S0264-410X(20)31593.
    >> Share

  260. DEGELING C, Williams J, Carter SM, Moss R, et al
    Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
    Vaccine. 2020 Dec 11. pii: S0264-410X(20)31577.
    >> Share

  261. RASTEGAR M, Tavana M, Meraj A, Mina H, et al
    An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31589.
    >> Share

  262. HOLM MR, Poland GA
    Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy.
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31584.
    >> Share

  263. CARIAS C, Pawaskar M, Nyaku M, Conway JH, et al
    Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US).
    Vaccine. 2020 Dec 9. pii: S0264-410X(20)31557.
    >> Share

  264. DHAKAL S, Deshpande S, McMahon M, Strohmeier S, et al
    Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31510.
    >> Share

  265. LENG A, Maitland E, Wang S, Nicholas S, et al
    Individual preferences for COVID-19 vaccination in China.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31576.
    >> Share

  266. GHIGA I, Richardson S, Alvarez AMR, Kato M, et al
    PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Vaccine. 2020 Dec 5. pii: S0264-410X(20)31500.
    >> Share

  267. WENZEL NS, Atkins KE, van Leeuwen E, Halloran ME, et al
    Cost-effectiveness of live-attenuated influenza vaccination among school-age children.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31282.
    >> Share

  268. MAYKIN MM, Heuser C, Feltovich H
    Pregnant people deserve the protection offered by SARS-CoV-2 vaccines.
    Vaccine. 2020 Dec 4. pii: S0264-410X(20)31572.
    >> Share

  269. BOTHUN LS
    COVID-19: The worst date to the senior dance.
    Vaccine. 2020;38:8066-8067.
    >> Share

    November 2020
  270. EDOKA I, Kohli-Lynch C, Fraser H, Hofman K, et al
    A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
    Vaccine. 2020 Nov 30. pii: S0264-410X(20)31468.
    >> Share

  271. HAVERI A, Ikonen N, Savolainen-Kopra C, Julkunen I, et al
    Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31494.
    >> Share

  272. VANDER STICHELE RH, Hay C, Fladvad M, Sturkenboom MCJM, et al
    How to ensure we can track and trace global use of COVID-19 vaccines?
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31508.
    >> Share

  273. KITANO T, Aoki H
    A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31506.
    >> Share

  274. URA T, Yamashita A, Mizuki N, Okuda K, et al
    New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Vaccine. 2020 Nov 24. pii: S0264-410X(20)31507.
    >> Share

  275. KITTIKRAISAK W, Phadungkiatwatana P, Ditsungnoen D, Kaoiean S, et al
    Comparison of influenza antibody titers among women who were vaccinated in the 2(nd) and the 3(rd) trimesters of pregnancy.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31472.
    >> Share

  276. DRORI Y, Pando R, Sefty H, Rosenberg A, et al
    Influenza vaccine effectiveness against laboratory-confirmed influenza in a vaccine-mismatched influenza B-dominant season.
    Vaccine. 2020 Nov 23. pii: S0264-410X(20)31394.
    >> Share

  277. GANGULY M, Yeolekar L, Tyagi P, Sagar U, et al
    Evaluation of manufacturing feasibility and safety of an MDCK cell-based live attenuated influenza vaccine (LAIV) platform.
    Vaccine. 2020 Nov 20. pii: S0264-410X(20)31424.
    >> Share

  278. TUCKERMAN JL, Kaufman J, Danchin M, Marshall HS, et al
    Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions.
    Vaccine. 2020;38:7806-7814.
    >> Share

  279. GARCIA LY, Cerda AA
    Acceptance of a COVID-19 vaccine: A multifactorial consideration.
    Vaccine. 2020;38:7587.
    >> Share

  280. GRAFFIGNA G, Palamenghi L, Barello S, Stefania B, et al
    "Cultivating" acceptance of a COVID-19 vaccination program: Lessons from Italy.
    Vaccine. 2020;38:7585-7586.
    >> Share

  281. COUDEVILLE L, Gomez GB, Jollivet O, Harris RC, et al
    Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Vaccine. 2020;38:7588-7595.
    >> Share

  282. ZHANG W, Gao J, Chen L, Tian J, et al
    Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons.
    Vaccine. 2020 Nov 8. pii: S0264-410X(20)31389.
    >> Share

  283. CHIU SS, Chua H, Kwan MYW, Chan ELY, et al
    Influenza vaccination effectiveness in preventing influenza hospitalization in children, Hong Kong, winter 2019/20.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31401.
    >> Share

  284. SARASTY O, Carpio CE, Hudson D, Guerrero-Ochoa PA, et al
    The demand for a COVID-19 vaccine in Ecuador.
    Vaccine. 2020 Nov 6. pii: S0264-410X(20)31439.
    >> Share

  285. KESKE S, Mutters NT, Tsioutis C, Ergonul O, et al
    Influenza vaccination among infection control teams: A EUCIC survey prior to COVID-19 pandemic.
    Vaccine. 2020 Nov 5. pii: S0264-410X(20)31427.
    >> Share

  286. CHEN WH, Tao X, Agrawal AS, Algaissi A, et al
    Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Vaccine. 2020;38:7533-7541.
    >> Share

    October 2020
  287. VESIKARI T, Ramsey K, Pitisuttithum P, Capeding R, et al
    Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31330.
    >> Share

  288. BONANNI P, Angelillo IF, Villani A, Biasci P, et al
    Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic: Appeal from the Board of the Vaccination Calendar for Life in Italy: Maintain and increase coverage also by r
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31318.
    >> Share

  289. CARCELEN AC, Vilajeliu A, Malik F, Gilman RH, et al
    Perceptions and attitudes towards vaccination during pregnancy in a peri urban area of Lima, Peru.
    Vaccine. 2020 Oct 30. pii: S0264-410X(20)31325.
    >> Share

  290. LIU B, Shi P, Wang T, Zhao Y, et al
    Recombinant H7 hemagglutinin expressed in glycoengineered Pichia pastoris forms nanoparticles that protect mice from challenge with H7N9 influenza virus.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31370.
    >> Share

  291. SCHNEIKART G, Tavarini S, Sammicheli C, Torricelli G, et al
    The respiratory syncytial virus fusion protein-specific B cell receptor repertoire reshaped by post-fusion subunit vaccination.
    Vaccine. 2020 Oct 29. pii: S0264-410X(20)31371.
    >> Share

  292. LIU X, Drelich A, Li W, Chen C, et al
    Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Vaccine. 2020;38:7205-7212.
    >> Share

  293. GUEBRE-XABIER M, Patel N, Tian JH, Zhou B, et al
    NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
    Vaccine. 2020 Oct 23. pii: S0264-410X(20)31373.
    >> Share

  294. CHANDIR S, Siddiqi DA, Mehmood M, Setayesh H, et al
    Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: An analysis of provincial electronic immunization registry data.
    Vaccine. 2020;38:7146-7155.
    >> Share

  295. RUSCIO BA, Hotez P
    Expanding global and national influenza vaccine systems to match the COVID-19 pandemic response.
    Vaccine. 2020 Oct 21. pii: S0264-410X(20)31364.
    >> Share

  296. BELL S, Clarke R, Mounier-Jack S, Walker JL, et al
    Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England.
    Vaccine. 2020 Oct 19. pii: S0264-410X(20)31321.
    >> Share

  297. ZHAI Y, Santibanez TA, Kahn KE, Srivastav A, et al
    Rural, urban, and suburban differences in influenza vaccination coverage among children.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31324.
    >> Share

  298. GARCIA PJ, George PE, Romero C, Soto G, et al
    "The flu... is a little more complicated than a cold": Knowledge, beliefs, and practices related to influenza and influenza vaccination among at-risk populations and health professionals in Peru.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31236.
    >> Share

  299. VERGKIZI S, Nikolakakis I
    Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31284.
    >> Share

  300. MALTEZOU HC, Theodoridou K, Tseroni M, Raftopoulos V, et al
    Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January-March 2020.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31276.
    >> Share

  301. MO Y, Zeng J, Xiao C, Zhang, et al
    Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis.
    Vaccine. 2020 Oct 12. pii: S0264-410X(20)31262.
    >> Share

  302. GOLDMAN RD, Yan TD, Seiler M, Parra Cotanda C, et al
    Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.
    Vaccine. 2020 Oct 10. pii: S0264-410X(20)31317.
    >> Share

  303. SAFAVI A, Kefayat A, Mahdevar E, Abiri A, et al
    Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31307.
    >> Share

  304. RONCATI L, Vadala M, Corazzari V, Palmieri B, et al
    COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31303.
    >> Share

  305. SINGH JA
    COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
    Vaccine. 2020 Oct 9. pii: S0264-410X(20)31302.
    >> Share

  306. MACIAS AE, McElhaney JE, Chaves SS, Nealon J, et al
    The disease burden of influenza beyond respiratory illness.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31209.
    >> Share

  307. GUILFOYLE K, Major D, Skeldon S, James H, et al
    Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31233.
    >> Share

  308. LEE JKH, Lam GKL, Shin T, Samson SI, et al
    Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis.
    Vaccine. 2020 Oct 6. pii: S0264-410X(20)31146.
    >> Share

  309. WOLF J, Hansen R, Hassis K, Lapps W, et al
    The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.
    Vaccine. 2020 Oct 5. pii: S0264-410X(20)31228.
    >> Share

  310. CUSTERS J, Kim D, Leyssen M, Gurwith M, et al
    Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2020 Oct 3. pii: S0264-410X(20)31160.
    >> Share

  311. HOSHI SL, Shono A, Seposo X, Okubo I, et al
    Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.
    Vaccine. 2020 Oct 2. pii: S0264-410X(20)31180.
    >> Share

  312. NIANG M, Deming ME, Goudiaby D, Diop OM, et al
    Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31230.
    >> Share

    September 2020
  313. TEMPIA S, Moyes J, Cohen AL, Walaza S, et al
    Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 Sep 23. pii: S0264-410X(20)31193.
    >> Share

  314. ANDREW MK, McNeil SA
    Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective.
    Vaccine. 2020 Sep 18. pii: S0264-410X(20)31153.
    >> Share

  315. DETOC M, Bruel S, Frappe P, Tardy B, et al
    Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.
    Vaccine. 2020 Sep 17. pii: S0264-410X(20)31201.
    >> Share

  316. ALHALASEH L, Fayoumi H, Khalil B
    The Health Belief Model in predicting healthcare workers' intention for influenza vaccine uptake in Jordan.
    Vaccine. 2020 Sep 16. pii: S0264-410X(20)31128.
    >> Share

  317. MCMAHON M, Strohmeier S, Rajendran M, Capuano C, et al
    Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice.
    Vaccine. 2020 Sep 15. pii: S0264-410X(20)31119.
    >> Share

  318. DEAN NE, Pastore Y Piontti A, Madewell ZJ, Cummings DAT, et al
    Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
    Vaccine. 2020 Sep 15. pii: S0264-410X(20)31191.
    >> Share

  319. BRUCE-STASKAL PJ, Woods RM, Borisov OV, Massare MJ, et al
    Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance.
    Vaccine. 2020 Sep 11. pii: S0264-410X(20)31078.
    >> Share

  320. WANG K, Wong ELY, Ho KF, Cheung AWL, et al
    Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey.
    Vaccine. 2020 Sep 10. pii: S0264-410X(20)31175.
    >> Share

  321. OTIENO NA, Nyawanda B, Otiato F, Adero M, et al
    Knowledge and attitudes towards influenza and influenza vaccination among pregnant women in Kenya.
    Vaccine. 2020 Sep 3. pii: S0264-410X(20)31046.
    >> Share

  322. LAU LHW, Lee SS, Wong NS
    The continuum of influenza vaccine hesitancy among nursing professionals in Hong Kong.
    Vaccine. 2020 Sep 2. pii: S0264-410X(20)31079.
    >> Share

    August 2020
  323. KASE T, Inoue M, Morikawa S, Kumashiro H, et al
    Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
    Vaccine. 2020 Aug 29. pii: S0264-410X(20)31066.
    >> Share

  324. TALAYEV V, Zaichenko I, Svetlova M, Matveichev A, et al
    Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity.
    Vaccine. 2020 Aug 29. pii: S0264-410X(20)30984.
    >> Share

  325. HOWE AS, Pointon L, Gauld N, Paynter J, et al
    Pertussis and influenza immunisation coverage of pregnant women in New Zealand.
    Vaccine. 2020 Aug 28. pii: S0264-410X(20)31071.
    >> Share

  326. AMIN AB, Nunes MC, Tapia MD, Madhi SA, et al
    Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa.
    Vaccine. 2020 Aug 28. pii: S0264-410X(20)30933.
    >> Share

  327. TOMITA Y, Sato R, Ikeda T, Sakagami T, et al
    BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31086.
    >> Share

  328. REITER PL, Pennell ML, Katz ML
    Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated?
    Vaccine. 2020 Aug 20. pii: S0264-410X(20)31084.
    >> Share

  329. PAGET J, Caini S, Cowling B, Esposito S, et al
    The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31065.
    >> Share

  330. GALILI U
    Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes.
    Vaccine. 2020 Aug 19. pii: S0264-410X(20)31073.
    >> Share

  331. ZHOU F, Lindley MC
    Variability in influenza vaccination opportunities and coverage among privately insured children.
    Vaccine. 2020 Aug 18. pii: S0264-410X(20)30992.
    >> Share

  332. HUNG MC, Lu PJ, Srivastav A, Cheng YJ, et al
    Influenza vaccination coverage among adults with diabetes, United States, 2007-08 through 2017-18 seasons.
    Vaccine. 2020 Aug 17. pii: S0264-410X(20)31029.
    >> Share

  333. NEWMAN KL, Stewart LM, Scott EM, Tielsch JM, et al
    Assessment of indirect protection from maternal influenza immunization among non-vaccinated household family members in a randomized controlled trial in Sarlahi, Nepal.
    Vaccine. 2020 Aug 17. pii: S0264-410X(20)31045.
    >> Share

  334. BENNETT N, Crouch S, Hoskins A, Malloy MJ, et al
    'Closing the gap': Evaluating the success of non-mandatory strategies for influenza vaccination of Victorian healthcare workers.
    Vaccine. 2020 Aug 12. pii: S0264-410X(20)31044.
    >> Share

  335. BALASUBRAMANI GK, Choi WS, Nowalk MP, Zimmerman RK, et al
    Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Vaccine. 2020 Aug 12. pii: S0264-410X(20)31032.
    >> Share

  336. GRADY C, Shah S, Miller F, Danis M, et al
    So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development.
    Vaccine. 2020 Aug 11. pii: S0264-410X(20)31048.
    >> Share

  337. KASSIANOS G, MacDonald P, Aloysius I, Reynolds A, et al
    Implementation of the United Kingdom's childhood influenza national vaccination programme: A review of clinical impact and lessons learned over six influenza seasons.
    Vaccine. 2020;38:5747-5758.
    >> Share

  338. FREW PM, Paine MB, Rouphael N, Schamel J, et al
    Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity.
    Vaccine. 2020 Aug 10. pii: S0264-410X(20)31006.
    >> Share

  339. YITBAREK K, Abraham G, Girma T, Tilahun T, et al
    The effect of Bacillus Calmette-Guerin (BCG) vaccination in preventing sever infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.
    Vaccine. 2020 Aug 10. pii: S0264-410X(20)31049.
    >> Share

  340. STUURMAN AL, Bollaerts K, Alexandridou M, Biccler J, et al
    Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19.
    Vaccine. 2020 Aug 7. pii: S0264-410X(20)31005.
    >> Share

  341. CHAN MS, Jamieson KH, Albarracin D
    Prospective associations of regional social media messages with attitudes and actual vaccination: A big data and survey study of the influenza vaccine in the United States.
    Vaccine. 2020 Aug 6. pii: S0264-410X(20)30985.
    >> Share

  342. MARELLAPUDI A, King AR, Bednarczyk RA
    Presentation of caregiver-specific vaccine-related information on National Cancer Institute designated cancer center websites.
    Vaccine. 2020 Aug 1. pii: S0264-410X(20)30983.
    >> Share

    July 2020
  343. REN W, Sun H, Gao GF, Chen J, et al
    Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
    Vaccine. 2020;38:5653-5658.
    >> Share

  344. WANG S, Zheng Y, Jin X, Gan Z, et al
    Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)30932.
    >> Share

  345. FORMAN R, Anderson M, Jit M, Mossialos E, et al
    Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)31012.
    >> Share

  346. KOCHHAR S, Excler JL, Kim D, Robertson JS, et al
    The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
    Vaccine. 2020 Jul 31. pii: S0264-410X(20)30944.
    >> Share

  347. YEOLEKAR LR, Guilfoyle K, Ganguly M, Tyagi P, et al
    Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30972.
    >> Share

  348. MAZAGATOS C, Godoy P, Munoz Almagro C, Pozo F, et al
    Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017-2019.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30914.
    >> Share

  349. ELLISON TJ, Talbott GC, Henderson DR
    VaxiPatch, a novel vaccination system comprised of subunit antigens, adjuvants and microneedle skin delivery: An application to influenza B/Colorado/06/2017.
    Vaccine. 2020 Jul 30. pii: S0264-410X(20)30958.
    >> Share

  350. DIVINO V, Krishnarajah G, Pelton SI, Mould-Quevedo J, et al
    A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30936.
    >> Share

  351. KIM YH, Bang YJ, Park HJ, Li Ko H, et al
    Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30935.
    >> Share

  352. MALTEZOU HC, Theodoridou K, Poland G
    Influenza immunization and COVID-19.
    Vaccine. 2020 Jul 29. pii: S0264-410X(20)30989.
    >> Share

  353. KIM HM, Kim DY, Kang YM, Cho HK, et al
    Immunogenicity and protective efficacy of clade 2.3.2.1c and clade 2.3.4.4c H5Nx avian influenza antigen bank vaccines in mice, Korea.
    Vaccine. 2020 Jul 27. pii: S0264-410X(20)30951.
    >> Share

  354. CHU K, Xu K, Tang R, Tian X, et al
    Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged >/=3 years.
    Vaccine. 2020 Jul 27. pii: S0264-410X(20)30872.
    >> Share

  355. VERDIJK P, van der Plas JL, van Brummelen EMJ, Jeeninga RE, et al
    First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial.
    Vaccine. 2020 Jul 25. pii: S0264-410X(20)30947.
    >> Share

  356. KAVIAN N, Hachim A, Poon LLM, Valkenburg SA, et al
    Vaccination with ADCC activating HA peptide epitopes provides 1 partial protection from influenza infection.
    Vaccine. 2020 Jul 24. pii: S0264-410X(20)30908.
    >> Share

  357. WEI J, Li Z, Yang Y, Ma X, et al
    A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy.
    Vaccine. 2020 Jul 23. pii: S0264-410X(20)30915.
    >> Share

  358. LEBRUN-HARRIS LA, Mendel Van Alstyne JA, Sripipatana A
    Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers.
    Vaccine. 2020 Jul 23. pii: S0264-410X(20)30934.
    >> Share

  359. MORO PL, Woo EJ, Marquez P, Cano M, et al
    Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Vaccine. 2020 Jul 21. pii: S0264-410X(20)30907.
    >> Share

  360. SAUNIER F, Berthelot P, Mottet-Auselo B, Pelissier C, et al
    Impact of a decision-aid tool on influenza vaccine coverage among HCW in two French hospitals: A cluster-randomized trial.
    Vaccine. 2020 Jul 16. pii: S0264-410X(20)30911.
    >> Share

  361. SKARLUPKA AL, Handel A, Ross TM
    Influenza hemagglutinin antigenic distance measures capture trends in HAI differences and infection outcomes, but are not suitable predictive tools.
    Vaccine. 2020 Jul 15. pii: S0264-410X(20)30828.
    >> Share

  362. JUNG YJ, Kim KH, Ko EJ, Lee Y, et al
    Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.
    Vaccine. 2020 Jul 13. pii: S0264-410X(20)30878.
    >> Share

  363. HASHEMZADEH A, Avan A, Ferns GA, Khazaei M, et al
    Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
    Vaccine. 2020 Jul 11. pii: S0264-410X(20)30903.
    >> Share

  364. KOCHHAR S, Salmon DA
    Planning for COVID-19 vaccines safety surveillance.
    Vaccine. 2020 Jul 10. pii: S0264-410X(20)30913.
    >> Share

  365. SU QD, Yi Y, Zou YN, Jia ZY, et al
    The biological characteristics of SARS-CoV-2 spike protein Pro330-Leu650.
    Vaccine. 2020;38:5071-5075.
    >> Share

  366. OSAMA EL-GENDY A, Saeed H, Ali AMA, Zawbaa HM, et al
    Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
    Vaccine. 2020 Jul 3. pii: S0264-410X(20)30886.
    >> Share

  367. MELIDOU A, Hungnes O, Pereyaslov D, Adlhoch C, et al
    Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018-2019.
    Vaccine. 2020 Jul 2. pii: S0264-410X(20)30804.
    >> Share

    June 2020
  368. BALZARINI F, Frascella B, Oradini-Alacreu A, Gaetti G, et al
    Does the use of personal electronic health records increase vaccine uptake? A systematic review.
    Vaccine. 2020 Jun 30. pii: S0264-410X(20)30738.
    >> Share

  369. RAJARAM S, Wojcik R, Moore C, Ortiz de Lejarazu R, et al
    The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30794.
    >> Share

  370. LEE H, Kim HJ, Choe YJ, Shin JY, et al
    Signals and trends of Guillain-Barre syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30824.
    >> Share

  371. PAGUIO JA, Yao JS, Dee EC
    Silver lining of COVID-19: Heightened global interest in pneumococcal and influenza vaccines, an infodemiology study.
    Vaccine. 2020 Jun 25. pii: S0264-410X(20)30855.
    >> Share

  372. GARCIA LY, Cerda AA
    Contingent assessment of the COVID-19 vaccine.
    Vaccine. 2020 Jun 25. pii: S0264-410X(20)30854.
    >> Share

  373. GUIDRY JPD, Coman IA, Vraga EK, O'Donnell NH, et al
    (S)pin the flu vaccine: Recipes for concern.
    Vaccine. 2020 Jun 24. pii: S0264-410X(20)30773.
    >> Share

  374. KARTOGLU UH, Moore KL, Lloyd JS
    Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers.
    Vaccine. 2020 Jun 23. pii: S0264-410X(20)30842.
    >> Share

  375. HENN W
    Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity.
    Vaccine. 2020 Jun 23. pii: S0264-410X(20)30844.
    >> Share

  376. BARAL R, Li X, Willem L, Antillon M, et al
    The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30822.
    >> Share

  377. MOEHLING KK, Zimmerman RK, Nowalk MP, Jeng Lin C, et al
    A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.
    Vaccine. 2020 Jun 21. pii: S0264-410X(20)30796.
    >> Share

  378. GRIECO L, Panovska-Griffiths J, van Leeuwen E, Grove P, et al
    Exploring the role of mass immunisation in influenza pandemic preparedness: A modelling study for the UK context.
    Vaccine. 2020 Jun 20. pii: S0264-410X(20)30805.
    >> Share

  379. VAN AALST R, Russo EM, Neupane N, Mahmud SM, et al
    Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable
    Vaccine. 2020 Jun 20. pii: S0264-410X(20)30735.
    >> Share

  380. ULYTE A, Wei W, Gruebner O, Bahler C, et al
    Insights into the protective effects of influenza vaccination: More hospitalizations but lower follow-up mortality during the 2014/15 influenza season in a Swiss cohort.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30791.
    >> Share

  381. MUNOZ FM, Patel SM, Jackson LA, Swamy GK, et al
    Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30704.
    >> Share

  382. THINDWA D, Garcia Quesada M, Liu Y, Bennett J, et al
    Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30833.
    >> Share

  383. WOLFF GG
    Letter to the Editor.
    Vaccine. 2020;38:4651.
    >> Share

  384. LAYTON JB, McGrath LJ, Sahrmann JM, Ma Y, et al
    Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.
    Vaccine. 2020 Jun 18. pii: S0264-410X(20)30793.
    >> Share

  385. KELLY MK, Grundmeier RW, Stephens-Shields AJ, Localio R, et al
    Missed opportunities for human papillomavirus vaccination at office visits during which influenza vaccine was administered: An AAP pediatric research in office settings (PROS) national primary care research network study.
    Vaccine. 2020 Jun 12. pii: S0264-410X(20)30757.
    >> Share

  386. COOKENHAM T, Lanzer KG, Gage E, Lorenzo EC, et al
    Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity.
    Vaccine. 2020 Jun 12. pii: S0264-410X(20)30752.
    >> Share

  387. AIDOUD A, Marlet J, Angoulvant D, Debacq C, et al
    Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30725.
    >> Share

  388. PAGLIUSI S, Jarrett S, Hayman B, Kreysa U, et al
    Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30795.
    >> Share

  389. CHOI EJ, Park JH, Chun BC
    Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea.
    Vaccine. 2020 Jun 9. pii: S0264-410X(20)30710.
    >> Share

  390. SCHAEFER GO, Tam CC, Savulescu J, Voo TC, et al
    COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Vaccine. 2020 Jun 4. pii: S0264-410X(20)30768.
    >> Share

  391. MORALES KF, Menning L, Lambach P
    The faces of influenza vaccine recommendation: A Literature review of the determinants and barriers to health providers' recommendation of influenza vaccine in pregnancy.
    Vaccine. 2020 Jun 2. pii: S0264-410X(20)30513.
    >> Share

  392. GLOVER C, Crawford N, Leeb A, Wood N, et al
    Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Vaccine. 2020 Jun 1. pii: S0264-410X(20)30560.
    >> Share

    May 2020
  393. POWELL AM, Luo Z, Martin L, Wan Z, et al
    Corrigendum to "The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals
    Vaccine. 2020 May 27. pii: S0264-410X(20)30673.
    >> Share

  394. LAMBERT PH, Ambrosino DM, Andersen SR, Baric RS, et al
    Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Vaccine. 2020 May 25. pii: S0264-410X(20)30709.
    >> Share

  395. PAUDEL M, Mahmud S, Buikema A, Korrer S, et al
    Relative vaccine efficacy of high-dose versus standard-dose influenza vaccines in preventing probable influenza in a Medicare Fee-for-Service population.
    Vaccine. 2020 May 20. pii: S0264-410X(20)30638.
    >> Share

  396. PLOTKIN SA, Caplan A
    Extraordinary diseases require extraordinary solutions.
    Vaccine. 2020;38:3987-3988.
    >> Share

  397. KOPSIDAS I, Tsopela GC, Maroudi-Manta S, Kourkouni E, et al
    Increasing healthcare workers' uptake of seasonal influenza vaccination in a tertiary-care pediatric hospital in Greece with a low-cost, tailor-made, multifaceted strategy.
    Vaccine. 2020 May 16. pii: S0264-410X(20)30639.
    >> Share

  398. ORTA OR, Hatch EE, Regan AK, Perkins R, et al
    A prospective study of influenza vaccination and time to pregnancy.
    Vaccine. 2020 May 11. pii: S0264-410X(20)30548.
    >> Share

  399. MALTEZOU HC, Asimakopoulos G, Stavrou S, Daskalakis G, et al
    Effectiveness of quadrivalent influenza vaccine in pregnant women and infants, 2018-2019.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30564.
    >> Share

  400. WON G, Senevirathne A, Lee JH
    Salmonella Enteritidis ghost vaccine carrying the hemagglutinin globular head (HA1) domain from H1N1 virus protects against salmonellosis and influenza in chickens.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30594.
    >> Share

  401. WRAITH S, Nachbagauer R, Balmaseda A, Stadlbauer D, et al
    Antibody responses to influenza A(H1N1)pdm infection.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30586.
    >> Share

  402. TEMPIA S, Walaza S, Moyes J, McMorrow ML, et al
    Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30539.
    >> Share

  403. LIAO Q, Ng TWY, Cowling BJ
    What influenza vaccination programmes are preferred by healthcare personnel? A discrete choice experiment.
    Vaccine. 2020 May 7. pii: S0264-410X(20)30630.
    >> Share

  404. WAGNER AL, Gordon A, Tallo VL, Simaku A, et al
    Intent to obtain pediatric influenza vaccine among mothers in four middle income countries.
    Vaccine. 2020 May 6. pii: S0264-410X(20)30508.
    >> Share

  405. FRANCIS MJ
    A Veterinary Vaccine Development Process Map to assist in the development of new vaccines.
    Vaccine. 2020 May 6. pii: S0264-410X(20)30613.
    >> Share

  406. SMITH LE, Amlot R, Weinman J, Yiend J, et al
    Why do parents not re-vaccinate their child for influenza? A prospective cohort study.
    Vaccine. 2020 May 5. pii: S0264-410X(20)30509.
    >> Share

  407. BELL S, Chantler T, Paterson P, Mounier-Jack S, et al
    Is flu vaccination opt-out feasible? Evidence from vaccination programme implementers and managers in the English National Health Service.
    Vaccine. 2020 May 4. pii: S0264-410X(20)30506.
    >> Share

  408. HAWKSWORTH A, Lockhart R, Crowe J, Maeso R, et al
    Replication of live attenuated influenza vaccine viruses in human nasal epithelial cells is associated with H1N1 vaccine effectiveness.
    Vaccine. 2020 May 3. pii: S0264-410X(20)30462.
    >> Share

    April 2020
  409. NGUYEN VH, Vizzotti C, Uruena A, Giglio N, et al
    Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Vaccine. 2020;38:3682-3689.
    >> Share

  410. HERST CV, Burkholz S, Sidney J, Sette A, et al
    An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.
    Vaccine. 2020 Apr 28. pii: S0264-410X(20)30518.
    >> Share

  411. WANG SH, Chen J, Smith D, Cao Z, et al
    A novel combination of intramuscular vaccine adjuvants, nanoemulsion and CpG produces an effective immune response against influenza A virus.
    Vaccine. 2020;38:3537-3544.
    >> Share

  412. HOSANGADI D, Warmbrod KL, Martin EK, Adalja A, et al
    Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.
    Vaccine. 2020 Apr 20. pii: S0264-410X(20)30530.
    >> Share

  413. KAUFMAN J, Attwell K, Tuckerman J, O'Sullivan J, et al
    Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study.
    Vaccine. 2020 Apr 19. pii: S0264-410X(20)30469.
    >> Share

  414. CROSS JW, Joy M, McGee C, Akinyemi O, et al
    Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018).
    Vaccine. 2020 Apr 13. pii: S0264-410X(20)30402.
    >> Share

  415. STAPLETON JT, Wagner N, Tuetken R, Bellamy AR, et al
    High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.
    Vaccine. 2020 Apr 12. pii: S0264-410X(20)30459.
    >> Share

  416. CHANG CY, Cho CY, Lai CC, Lu CY, et al
    Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30437.
    >> Share

  417. SUGISHITA Y, Nakayama T, Sugawara T, Ohkusa Y, et al
    Negative effect on immune response of repeated influenza vaccination and waning effectiveness in interseason for elderly people.
    Vaccine. 2020 Apr 7. pii: S0264-410X(20)30378.
    >> Share

  418. SURAGH TA, Hibbs B, Marquez P, McNeil MM, et al
    Age inappropriate influenza vaccination in infants less than 6 months old, 2010-2018.
    Vaccine. 2020 Apr 6. pii: S0264-410X(20)30418.
    >> Share

    March 2020
  419. AHMED MA, Naus M, Singer J, Valiquette L, et al
    Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13-2016/17, the Canadian Vaccine Safety Network.
    Vaccine. 2020 Mar 27. pii: S0264-410X(20)30371.
    >> Share

  420. O'LEARY ST, Cataldi JR, Lindley MC, Hurley LP, et al
    Impact of media reports regarding influenza vaccine on obstetricians' vaccination practices.
    Vaccine. 2020 Mar 21. pii: S0264-410X(20)30263.
    >> Share

  421. LANE MC, Gordon JL, Jiang C, Leitner WW, et al
    Workshop report: Optimization of animal models to better predict influenza vaccine efficacy.
    Vaccine. 2020;38:2751-2757.
    >> Share

  422. NEUMANN G, Kawaoka Y
    Optimization of animal models to better predict influenza vaccine efficacy (VA).
    Vaccine. 2020;38:2749-2750.
    >> Share

  423. RUSCIO B, Bolster A, Bresee J
    Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness.
    Vaccine. 2020 Mar 11. pii: S0264-410X(20)30247.
    >> Share

  424. BRAEYE T, Emborg HD, Llorente-Garcia A, Huerta C, et al
    Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project.
    Vaccine. 2020 Mar 11. pii: S0264-410X(20)30326.
    >> Share

  425. CHO HK, Kang YM, Kim HM, Lee CH, et al
    Sales and immunogenicity of commercial vaccines to H9N2 low pathogenic avian influenza virus in Korea from 2007 to 2017.
    Vaccine. 2020 Mar 10. pii: S0264-410X(20)30328.
    >> Share

  426. MOUNIER-JACK S, Bell S, Chantler T, Edwards A, et al
    Organisational factors affecting performance in delivering influenza vaccination to staff in NHS Acute Hospital Trusts in England: A qualitative study.
    Vaccine. 2020 Mar 5. pii: S0264-410X(20)30321.
    >> Share

  427. BELONGIA EA, Levine MZ, Olaiya O, Gross FL, et al
    Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Vaccine. 2020 Mar 4. pii: S0264-410X(20)30278.
    >> Share

  428. DRISCOLL AJ, Arshad SH, Bont L, Brunwasser SM, et al
    Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.
    Vaccine. 2020;38:2435-2448.
    >> Share

    February 2020
  429. POLAND GA
    Another coronavirus, another epidemic, another warning.
    Vaccine. 2020;38:v-vi.
    >> Share

  430. NABER SK, Bruijning-Verhagen PCJL, de Hoog MLA, van Giessen A, et al
    Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Vaccine. 2020 Feb 27. pii: S0264-410X(20)30084.
    >> Share

  431. KALLIGEROS M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, et al
    Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis.
    Vaccine. 2020 Feb 27. pii: S0264-410X(20)30261.
    >> Share

  432. BLYTH CC, Cheng AC, Crawford NW, Clark JE, et al
    The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018.
    Vaccine. 2020 Feb 24. pii: S0264-410X(20)30228.
    >> Share

  433. MUELLER S, Stauft CB, Kalkeri R, Koidei F, et al
    A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.
    Vaccine. 2020 Feb 24. pii: S0264-410X(20)30279.
    >> Share

  434. MOHAMMED H, Roberts CT, Grzeskowiak LE, Giles L, et al
    Psychosocial determinants of pertussis and influenza vaccine uptake in pregnant women: A prospective study.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30217.
    >> Share

  435. HOSCHLER K, Maharjan S, Whitaker H, Southern J, et al
    Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.
    Vaccine. 2020 Feb 15. pii: S0264-410X(20)30221.
    >> Share

  436. SAMY N, Reichhardt D, Schmidt D, Chen LM, et al
    Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.
    Vaccine. 2020 Feb 11. pii: S0264-410X(20)30081.
    >> Share

  437. FAN J, Cong S, Wang N, Bao H, et al
    Influenza vaccination rate and its association with chronic diseases in China: Results of a national cross-sectional study.
    Vaccine. 2020 Feb 8. pii: S0264-410X(20)30146.
    >> Share

  438. SICCA F, Martinuzzi D, Montomoli E, Huckriede A, et al
    Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement.
    Vaccine. 2020 Feb 7. pii: S0264-410X(20)30141.
    >> Share

  439. PULLAGURA GR, Violette R, Houle SKD, Waite NM, et al
    Shades of gray in vaccination decisions - Understanding community pharmacists' perspectives of, and experiences with, influenza vaccine hesitancy in Ontario, Canada.
    Vaccine. 2020 Feb 6. pii: S0264-410X(20)30137.
    >> Share

  440. VANDERVEN HA, Barr I, Reynaldi A, Wheatley AK, et al
    Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults.
    Vaccine. 2020 Feb 5. pii: S0264-410X(20)30104.
    >> Share

  441. HALES C, Jochems SP, Robinson R, Solorzano C, et al
    Symptoms associated with influenza vaccination and experimental human pneumococcal colonisation of the nasopharynx.
    Vaccine. 2020 Feb 4. pii: S0264-410X(20)30112.
    >> Share

  442. MOURATIDOU E, Lambrou A, Andreopoulou A, Gioula G, et al
    Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019.
    Vaccine. 2020 Feb 4. pii: S0264-410X(20)30135.
    >> Share

  443. BAKER MA, Jankosky C, Yih WK, Gruber S, et al
    The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines.
    Vaccine. 2020 Feb 1. pii: S0264-410X(20)30072.
    >> Share

    January 2020
  444. LU Y, Landreth S, Liu G, Brownlie R, et al
    Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.
    Vaccine. 2020 Jan 31. pii: S0264-410X(20)30077.
    >> Share

  445. AKPALU Y, Sullivan SJ, Regan AK
    Association between health insurance coverage and uptake of seasonal influenza vaccine in Brazos County, Texas.
    Vaccine. 2020 Jan 31. pii: S0264-410X(20)30044.
    >> Share

  446. AVALOS LA, Ferber J, Zerbo O, Naleway AL, et al
    Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development.
    Vaccine. 2020 Jan 29. pii: S0264-410X(20)30086.
    >> Share

  447. NGUYEN TTM, Lafond KE, Nguyen TX, Tran PD, et al
    Acceptability of seasonal influenza vaccines among health care workers in Vietnam in 2017.
    Vaccine. 2020 Jan 27. pii: S0264-410X(19)31699.
    >> Share

  448. KING JP, Hanson KE, Donahue JG, Glanz JM, et al
    Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016-17 season.
    Vaccine. 2020 Jan 25. pii: S0264-410X(20)30054.
    >> Share

  449. KAZAKOVA A, Kakkola L, Ziegler T, Syrjanen R, et al
    Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods.
    Vaccine. 2020 Jan 24. pii: S0264-410X(20)30037.
    >> Share

  450. LAI E, Tan HY, Kunasekaran M, Chughtai AA, et al
    Influenza vaccine coverage and predictors of vaccination among aged care workers in Sydney Australia.
    Vaccine. 2020 Jan 23. pii: S0264-410X(20)30008.
    >> Share

  451. CASTILLA J, Portillo ME, Casado I, Pozo F, et al
    Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018-2019.
    Vaccine. 2020 Jan 22. pii: S0264-410X(20)30043.
    >> Share

  452. MCDONALD JU, Rigsby P, Atkinson E, Engelhardt OG, et al
    Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study.
    Vaccine. 2020;38:800-807.
    >> Share

  453. CHROMIKOVA V, Tan J, Aslam S, Rajabhathor A, et al
    Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.
    Vaccine. 2020 Jan 17. pii: S0264-410X(20)30012.
    >> Share

  454. MA P, Luo Z, Qian J, Yan Z, et al
    Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.
    Vaccine. 2020 Jan 13. pii: S0264-410X(20)30004.
    >> Share

  455. HUANG C, Fu X, Zhou Y, Mi F, et al
    Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Vaccine. 2020 Jan 13. pii: S0264-410X(19)31625.
    >> Share

  456. XU L, Qin Z, Qiao L, Wen J, et al
    Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates.
    Vaccine. 2020 Jan 11. pii: S0264-410X(19)31718.
    >> Share

  457. JARVIS JR, Dorey RB, Warricker FDM, Alwan NA, et al
    The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: Systematic review and meta-analysis.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31720.
    >> Share

  458. SANDHU SK, Hua W, MaCurdy TE, Franks RL, et al
    Comparison of alpha-spending plans for near real-time monitoring for Guillain-Barre after influenza vaccination during the 2010/11 influenza season.
    Vaccine. 2020 Jan 10. pii: S0264-410X(19)31674.
    >> Share

  459. RAINISCH G, Adhikari B, Meltzer MI, Langley G, et al
    Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Vaccine. 2020;38:251-257.
    >> Share

    December 2019
  460. LUTZ CS, Fink RV, Cloud AJ, Stevenson J, et al
    Factors associated with perceptions of influenza vaccine safety and effectiveness among adults, United States, 2017-2018.
    Vaccine. 2019 Dec 27. pii: S0264-410X(19)31644.
    >> Share

  461. BEYER WEP, Palache AM, Reperant LA, Boulfich M, et al
    Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines.
    Vaccine. 2019 Dec 23. pii: S0264-410X(19)31679.
    >> Share

  462. GIESE H, Neth H, Moussaid M, Betsch C, et al
    The echo in flu-vaccination echo chambers: Selective attention trumps social influence.
    Vaccine. 2019 Dec 18. pii: S0264-410X(19)31563.
    >> Share

  463. RAO S, Ziniel SI, Khan I, Dempsey A, et al
    Be inFLUential: Evaluation of a multifaceted intervention to increase influenza vaccination rates among pediatric inpatients.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31652.
    >> Share

  464. BERTRAN K, Criado MF, Lee DH, Killmaster L, et al
    Protection of White Leghorn chickens by recombinant fowlpox vector vaccine with an updated H5 insert against Mexican H5N2 avian influenza viruses.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31626.
    >> Share

  465. DHAMAYANTI M, Tarigan R, Fadlyana E, Prasetyo D, et al
    Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31650.
    >> Share

  466. OFFEDDU V, Low MSF, Surendran S, Kembhavi G, et al
    Acceptance and feasibility of school-based seasonal influenza vaccination in Singapore: A qualitative study.
    Vaccine. 2019 Dec 17. pii: S0264-410X(19)31662.
    >> Share

  467. DE HOOG MLA, Venekamp RP, Meijer A, Sanders EAM, et al
    Inactivated influenza vaccine does not reduce all cause respiratory illness in children with pre-existing medical conditions.
    Vaccine. 2019 Dec 16. pii: S0264-410X(19)31640.
    >> Share

  468. PORTER RM, Goldin S, Lafond KE, Hedman L, et al
    Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic.
    Vaccine. 2019 Dec 12. pii: S0264-410X(19)31548.
    >> Share

  469. GAO Z, Robinson K, Skowronski DM, De Serres G, et al
    Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.
    Vaccine. 2019 Dec 6. pii: S0264-410X(19)31570.
    >> Share

  470. DUONG TN, Thiem VD, Anh DD, Cuong NP, et al
    A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
    Vaccine. 2019 Dec 4. pii: S0264-410X(19)31601.
    >> Share

  471. PAN SC, Hsu WT, Lee WS, Wang NC, et al
    A double-blind, randomized controlled trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with the adjuvant LTh(alphaK): A phase II study.
    Vaccine. 2019 Dec 4. pii: S0264-410X(19)31589.
    >> Share

  472. WILSON R, Zaytseva A, Bocquier A, Nokri A, et al
    Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France.
    Vaccine. 2019 Dec 3. pii: S0264-410X(19)31541.
    >> Share

  473. LAMA Y, Hancock GR, Freimuth VS, Jamison AM, et al
    Using classification and regression tree analysis to explore parental influenza vaccine decisions.
    Vaccine. 2019 Dec 2. pii: S0264-410X(19)31568.
    >> Share

    November 2019
  474. MALLORY RM, Nyborg A, Kalyani RN, Yuan Y, et al
    A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
    Vaccine. 2019 Nov 30. pii: S0264-410X(19)31597.
    >> Share

  475. LEE WN, Stuck D, Konty K, Rivers C, et al
    Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial.
    Vaccine. 2019 Nov 29. pii: S0264-410X(19)31595.
    >> Share

  476. JIANG M, Li P, Wang W, Zhao M, et al
    Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31587.
    >> Share

  477. REINDERS S, Romero C, Carcamo C, Tinoco Y, et al
    A community-based survey on influenza and vaccination knowledge, perceptions and practices in Peru.
    Vaccine. 2019 Nov 28. pii: S0264-410X(19)31539.
    >> Share

  478. PENTA MA, Craciun IC, Baban A
    The power of anticipated regret: Predictors of HPV vaccination and seasonal influenza vaccination acceptability among young Romanians.
    Vaccine. 2019 Nov 27. pii: S0264-410X(19)31571.
    >> Share

  479. HIBBS BF, Ng CS, Museru O, Moro PL, et al
    Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017.
    Vaccine. 2019 Nov 26. pii: S0264-410X(19)31546.
    >> Share

  480. GOSS MD, Temte JL, Barlow S, Temte E, et al
    An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination.
    Vaccine. 2019 Nov 25. pii: S0264-410X(19)31569.
    >> Share

  481. FURER V, Zisman D, Kaufman I, Arad U, et al
    Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.
    Vaccine. 2019 Nov 22. pii: S0264-410X(19)31470.
    >> Share

  482. NOWAK GJ, Evans NJ, Wojdynski BW, Ahn SJG, et al
    Using immersive virtual reality to improve the beliefs and intentions of influenza vaccine avoidant 18-to-49-year-olds: Considerations, effects, and lessons learned.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31516.
    >> Share

  483. WELLIVER RC, Papin JF, Preno A, Ivanov V, et al
    Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Vaccine. 2019 Nov 21. pii: S0264-410X(19)31510.
    >> Share

  484. FLOREK K, Mutschler J, McLean HQ, King JP, et al
    Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
    Vaccine. 2019 Nov 18. pii: S0264-410X(19)31440.
    >> Share

  485. PATEL MM, Davis W, Beacham L, Spencer S, et al
    Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children - A systematic review and a meta-analysis.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31433.
    >> Share

  486. SMATTI MK, Nasrallah GK, Al Thani AA, Yassine HM, et al
    Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent cellular cytotoxicity (ADCC) in human sera using novel stabilized stem nanoparticle probes.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31493.
    >> Share

  487. TSUZUKI S, Baguelin M, Pebody R, van Leeuwen E, et al
    Modelling the optimal target age group for seasonal influenza vaccination in Japan.
    Vaccine. 2019 Nov 14. pii: S0264-410X(19)31508.
    >> Share

  488. NUNEZ IA, Ross TM
    Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses.
    Vaccine. 2019 Nov 13. pii: S0264-410X(19)31497.
    >> Share

  489. KLAUSBERGER M, Leneva IA, Egorov A, Strobl F, et al
    Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections.
    Vaccine. 2019 Nov 9. pii: S0264-410X(19)31472.
    >> Share

  490. TADOUNT F, Doyon-Plourde P, Quach C
    Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review.
    Vaccine. 2019 Nov 8. pii: S0264-410X(19)31480.
    >> Share

  491. HAWKSWORTH A, Jayachander M, Hester S, Mohammed S, et al
    Proteomics as a tool for live attenuated influenza vaccine characterisation.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31471.
    >> Share

  492. KONGCHANAGUL A, Samnuan K, Wirachwong P, Surichan S, et al
    A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31473.
    >> Share

  493. GANCZAK M, Kalinowski P, Drozd-Dabrowska M, Biesiada D, et al
    School life and influenza immunization: A cross-sectional study on vaccination coverage and influencing determinants among Polish teachers.
    Vaccine. 2019 Nov 6. pii: S0264-410X(19)31447.
    >> Share

  494. BROWNE SK, Beeler JA, Roberts JN
    Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naive infants.
    Vaccine. 2019 Nov 6. pii: S0264-410X(19)31428.
    >> Share

  495. MANTEL C, Chu SY, Hyde TB, Lambach P, et al
    Seasonal influenza vaccination in middle-income countries: Assessment of immunization practices in Belarus, Morocco, and Thailand.
    Vaccine. 2019 Nov 4. pii: S0264-410X(19)31401.
    >> Share

  496. CHEN W, Stoecker C
    Mass media coverage and influenza vaccine uptake.
    Vaccine. 2019 Nov 4. pii: S0264-410X(19)31382.
    >> Share

  497. SONG JY, Noh JY, Lee JS, Wie SH, et al
    Effectiveness of repeated influenza vaccination among the elderly population with high annual vaccine uptake rates during the three consecutive A/H3N2 epidemics.
    Vaccine. 2019 Nov 2. pii: S0264-410X(19)31375.
    >> Share

  498. PEBODY RG, Whitaker H, Ellis J, Andrews N, et al
    End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19.
    Vaccine. 2019 Nov 1. pii: S0264-410X(19)31460.
    >> Share

    October 2019
  499. OTTEN G, Matassa V, Ciarlet M, Leav B, et al
    A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults>/=65 years of age.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31438.
    >> Share

  500. SHEN AK, Warnock R, Selna W, MaCurdy TE, et al
    Characteristics of vaccinating providers reported through Medicare claims in office-based settings: Volume of influenza and pneumococcal vaccinations.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31402.
    >> Share

  501. STURKENBOOM M, Bahri P, Chiucchiuini A, Grove Krause T, et al
    Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.
    Vaccine. 2019 Oct 31. pii: S0264-410X(19)31002.
    >> Share

  502. PALLAS SW, Ahmeti A, Morgan W, Preza I, et al
    Program cost analysis of influenza vaccination of health care workers in Albania.
    Vaccine. 2019 Oct 25. pii: S0264-410X(19)31400.
    >> Share

  503. KANG YM, Cho HK, Kim HM, Lee MH, et al
    Protective efficacy of vaccines of the Korea national antigen bank against the homologous H5Nx clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Vaccine. 2019 Oct 25. pii: S0264-410X(19)31417.
    >> Share

  504. NG TWY, Cowling BJ, So HC, Ip DKM, et al
    Testing an integrative theory of health behavioural change for predicting seasonal influenza vaccination uptake among healthcare workers.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31414.
    >> Share

  505. KOLB EA, Buterbaugh RE, Rinehart CL, Ensley D, et al
    Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.
    Vaccine. 2019 Oct 24. pii: S0264-410X(19)31378.
    >> Share

  506. FRAWLEY JE, McManus K, McIntyre E, Seale H, et al
    Uptake of funded influenza vaccines in young Australian children in 2018; parental characteristics, information seeking and attitudes.
    Vaccine. 2019 Oct 23. pii: S0264-410X(19)31406.
    >> Share

  507. PEBODY R, Whitaker H, Zhao H, Andrews N, et al
    Protection provided by influenza vaccine against influenza-related hospitalisation in >/=65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.
    Vaccine. 2019 Oct 22. pii: S0264-410X(19)31405.
    >> Share

  508. PEBODY RG, Zhao H, Whitaker HJ, Ellis J, et al
    Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.
    Vaccine. 2019 Oct 21. pii: S0264-410X(19)31408.
    >> Share

  509. FRIEDMAN L, Renaud A, Hines D, Winter A, et al
    Exploring indirect protection associated with influenza immunization - A systematic review of the literature.
    Vaccine. 2019 Oct 21. pii: S0264-410X(19)31328.
    >> Share

  510. ESSINK B, Fierro C, Rosen J, Figueroa AL, et al
    Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Vaccine. 2019 Oct 18. pii: S0264-410X(19)31384.
    >> Share

  511. MANDON ED, Pizzorno A, Traversier A, Champagne A, et al
    Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.
    Vaccine. 2019 Oct 17. pii: S0264-410X(19)31381.
    >> Share

  512. WOLFF GG
    Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season.
    Vaccine. 2019 Oct 10. pii: S0264-410X(19)31364.
    >> Share

  513. ROBERTS NJ JR
    Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines.
    Vaccine. 2019 Oct 10. pii: S0264-410X(19)31339.
    >> Share

  514. VAN AALST R, Gravenstein S, Mor V, Mahmud SM, et al
    Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study.
    Vaccine. 2019 Oct 9. pii: S0264-410X(19)31349.
    >> Share

  515. BUFFIN S, Peubez I, Barriere F, Nicolai MC, et al
    Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies.
    Vaccine. 2019 Oct 4. pii: S0264-410X(19)31281.
    >> Share

  516. KOIKE ME, Gattas VL, Lucchesi MBB, Moura de Oliveira MM, et al
    Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan.
    Vaccine. 2019 Oct 4. pii: S0264-410X(19)31324.
    >> Share

    September 2019
  517. SMITH D, Streatfield SJ, Acosta H, Ganesan S, et al
    A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
    Vaccine. 2019;37:6162-6170.
    >> Share

  518. RUDICELL RS, Garinot M, Kanekiyo M, Kamp HD, et al
    Comparison of adjuvants to optimize influenza neutralizing antibody responses.
    Vaccine. 2019;37:6208-6220.
    >> Share

  519. BIGGERSTAFF M, Cohen C, Reed C, Tempia S, et al
    A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.
    Vaccine. 2019 Sep 28. pii: S0264-410X(19)31283.
    >> Share

  520. CUTRELL JB, Drechsler H, Bedimo R, Alvarez CA, et al
    Statin use and medically attended acute respiratory illness among influenza vaccine recipients.
    Vaccine. 2019 Sep 19. pii: S0264-410X(19)31224.
    >> Share

  521. GUCLU OA, Demirci H, Ocakoglu G, Guclu Y, et al
    Relationship of pneumococcal and influenza vaccination frequency with health literacy in the rural population in Turkey.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31258.
    >> Share

  522. YITBAREK A, Astill J, Hodgins DC, Parkinson J, et al
    Commensal gut microbiota can modulate adaptive immune responses in chickens vaccinated with whole inactivated avian influenza virus subtype H9N2.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31255.
    >> Share

  523. TEO LM, Smith HE, Lwin MO, Tang WE, et al
    Attitudes and perception of influenza vaccines among older people in Singapore: A qualitative study.
    Vaccine. 2019 Sep 18. pii: S0264-410X(19)31246.
    >> Share

  524. DONAHUE JG, Kieke BA, King JP, Mascola MA, et al
    Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.
    Vaccine. 2019 Sep 17. pii: S0264-410X(19)31244.
    >> Share

  525. GILES ML, Buttery J, Davey MA, Wallace E, et al
    Pregnant women's knowledge and attitude to maternal vaccination including group B streptococcus and respiratory syncytial virus vaccines.
    Vaccine. 2019 Sep 17. pii: S0264-410X(19)31173.
    >> Share

  526. TAN HY, Lai E, Kunasekaran M, Chughtai AA, et al
    Prevalence and predictors of influenza vaccination among residents of long-term care facilities.
    Vaccine. 2019 Sep 13. pii: S0264-410X(19)31221.
    >> Share

  527. HONEMANN M, Martin D, Pietsch C, Maier M, et al
    Influenza B virus infections in Western Saxony, Germany in three consecutive seasons between 2015 and 2018: Analysis of molecular and clinical features.
    Vaccine. 2019 Sep 11. pii: S0264-410X(19)31091.
    >> Share

  528. COSTANTINO V, MacIntyre CR, Trent M
    Modelling of optimal timing for influenza vaccination as a function of intraseasonal waning of immunity and vaccine coverage.
    Vaccine. 2019 Sep 11. pii: S0264-410X(19)31145.
    >> Share

  529. QUATTROCCHI A, Mereckiene J, Fitzgerald M, Cotter S, et al
    Determinants of influenza and pertussis vaccine uptake in pregnant women in Ireland: A cross-sectional survey in 2017/18 influenza season.
    Vaccine. 2019 Sep 9. pii: S0264-410X(19)31196.
    >> Share

  530. ARYA DP, Said MA, Izurieta HS, Perez-Vilar S, et al
    Surveillance for Guillain-Barre syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
    Vaccine. 2019 Sep 9. pii: S0264-410X(19)31109.
    >> Share

  531. ELAISH M, Xia M, Ngunjiri JM, Ghorbani A, et al
    Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens.
    Vaccine. 2019 Sep 7. pii: S0264-410X(19)31171.
    >> Share

  532. NAKAMURA K, Harada Y, Takahashi H, Trusheim H, et al
    Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and LLC-MK2 cells for preparing influenza vaccine seed virus.
    Vaccine. 2019 Sep 6. pii: S0264-410X(19)31140.
    >> Share

  533. CHERIAN T, Morales KF, Mantel C, Lambach P, et al
    Factors and considerations for establishing and improving seasonal influenza vaccination of health workers: Report from a WHO meeting, January 16-17, Berlin, Germany.
    Vaccine. 2019 Sep 6. pii: S0264-410X(19)31000.
    >> Share

    August 2019
  534. BAR-PELED Y, Huang J, Nunez IA, Pierce SR, et al
    Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.
    Vaccine. 2019 Aug 31. pii: S0264-410X(19)31138.
    >> Share

  535. RAJ SM, Chughtai AA, Sharma A, Tan TC, et al
    Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64years old.
    Vaccine. 2019 Aug 28. pii: S0264-410X(19)31092.
    >> Share

  536. CARLSON SJ, Scanlan C, Marshall HS, Blyth CC, et al
    Attitudes about and access to influenza vaccination experienced by parents of children hospitalised for influenza in Australia.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31071.
    >> Share

  537. DORAIVELU K, Boulet SL, Biswas HH, Adams JC, et al
    Predictors of tetanus, diphtheria, acellular pertussis and influenza vaccination during pregnancy among full-term deliveries in a medically underserved population.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31108.
    >> Share

  538. CHEN P, Ding L, Jiang Y, Zeng X, et al
    Protective efficacy in farmed ducks of a duck enteritis virus-vectored vaccine against H5N1, H5N6, and H5N8 avian influenza viruses.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31088.
    >> Share

  539. BRUXVOORT KJ, Luo Y, Ackerson B, Tanenbaum HC, et al
    Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018.
    Vaccine. 2019 Aug 21. pii: S0264-410X(19)31074.
    >> Share

  540. CHANG LJ, Meng Y, Janosczyk H, Landolfi V, et al
    Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults >/=65years of age: A phase 3 randomized clinical trial.
    Vaccine. 2019 Aug 17. pii: S0264-410X(19)31066.
    >> Share

  541. COSTANTINO C, Restivo V, Amodio E, Colomba GME, et al
    A mid-term estimate of 2018/2019 vaccine effectiveness to prevent laboratory confirmed A(H1N1)pdm09 and A(H3N2) influenza cases in Sicily (Italy).
    Vaccine. 2019 Aug 16. pii: S0264-410X(19)31064.
    >> Share

  542. BELINGHERI M, De Vito G, Riva MA
    Italian midwives and influenza vaccination: problems in adherence and perception.
    Vaccine. 2019;37:4851.
    >> Share

  543. INNIS BL, Scorza FB, Blum JS, Jain VK, et al
    Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.
    Vaccine. 2019;37:4830-4834.
    >> Share

  544. INNIS BL, Berlanda Scorza F, Blum JS, Jain VK, et al
    Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity.
    Vaccine. 2019;37:4823-4829.
    >> Share

  545. PATEL N, Massare MJ, Tian JH, Guebre-Xabier M, et al
    Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Vaccine. 2019 Aug 12. pii: S0264-410X(19)31010.
    >> Share

  546. ASTHAGIRI ARUNKUMAR G, McMahon M, Pavot V, Aramouni M, et al
    Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.
    Vaccine. 2019 Aug 6. pii: S0264-410X(19)31016.
    >> Share

  547. GEBAUER M, Hurlimann HC, Behrens M, Wolff T, et al
    Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme.
    Vaccine. 2019 Aug 6. pii: S0264-410X(19)31015.
    >> Share

  548. STARK FC, Akache B, Ponce A, Dudani R, et al
    Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.
    Vaccine. 2019 Aug 2. pii: S0264-410X(19)30888.
    >> Share

  549. TZENG TT, Lai CC, Weng TC, Cyue MH, et al
    The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses.
    Vaccine. 2019 Aug 2. pii: S0264-410X(19)30346.
    >> Share

    July 2019
  550. NOH JY, Jang YS, Lee SN, Choi MJ, et al
    Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Vaccine. 2019 Jul 31. pii: S0264-410X(19)30997.
    >> Share

  551. MUNOZ FM, Anderson EJ, Bernstein DI, Harrison CJ, et al
    Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
    Vaccine. 2019 Jul 30. pii: S0264-410X(19)31006.
    >> Share

  552. VENEREO-SANCHEZ A, Fulton K, Koczka K, Twine S, et al
    Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30955.
    >> Share

  553. ESTEBAN-VASALLO MD, Dominguez-Berjon MF, Garcia-Riolobos C, Zoni AC, et al
    Effect of mobile phone text messaging for improving the uptake of influenza vaccination in patients with rare diseases.
    Vaccine. 2019 Jul 25. pii: S0264-410X(19)30970.
    >> Share

  554. TATEISHI K, Fujihashi K, Yamamoto N, Hasegawa H, et al
    CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.
    Vaccine. 2019 Jul 22. pii: S0264-410X(19)30923.
    >> Share

  555. LEMIEUX M, Lorbetskie B, Luebbert CC, Walrond L, et al
    The differential effect of sub-micron level HA aggregates on influenza potency assays.
    Vaccine. 2019 Jul 20. pii: S0264-410X(19)30948.
    >> Share

  556. FABIANI M, Volpe E, Faraone M, Bella A, et al
    Influenza vaccine uptake in the elderly population: Individual and general practitioner's determinants in Central Italy, Lazio region, 2016-2017 season.
    Vaccine. 2019 Jul 19. pii: S0264-410X(19)30952.
    >> Share

  557. SIMOES EAF, Nunes MC, Carosone-Link P, Madimabe R, et al
    Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes.
    Vaccine. 2019 Jul 19. pii: S0264-410X(19)30915.
    >> Share

  558. EICKHOFF CS, Terry FE, Peng L, Meza KA, et al
    Highly conserved influenza T cell epitopes induce broadly protective immunity.
    Vaccine. 2019 Jul 19. pii: S0264-410X(19)30924.
    >> Share

  559. GOCKO X, Poulteau S, Beyens MN, Bertholon P, et al
    Case report: Recurrent peripheral facial paralysis following two influenza vaccinations in 2009 and 2016.
    Vaccine. 2019 Jul 13. pii: S0264-410X(19)30916.
    >> Share

  560. SHELDENKAR A, Lim F, Yung CF, Lwin MO, et al
    Acceptance and uptake of influenza vaccines in Asia: A systematic review.
    Vaccine. 2019 Jul 10. pii: S0264-410X(19)30889.
    >> Share

  561. KINGSTAD-BAKKE BA, Chandrasekar SS, Phanse Y, Ross KA, et al
    Effective mosaic-based nanovaccines against avian influenza in poultry.
    Vaccine. 2019 Jul 9. pii: S0264-410X(19)30854.
    >> Share

  562. BRESEE JS, Lafond KE, McCarron M, Azziz-Baumgartner E, et al
    The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships.
    Vaccine. 2019 Jul 6. pii: S0264-410X(19)30811.
    >> Share

  563. MOSER MJ, Hatta Y, Gabaglia C, Sanchez A, et al
    Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
    Vaccine. 2019 Jul 4. pii: S0264-410X(19)30805.
    >> Share

  564. PARKER L, Ritter L, Wu W, Maeso R, et al
    Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013-2014 and 2015-2016 seasons.
    Vaccine. 2019 Jul 3. pii: S0264-410X(19)30777.
    >> Share

  565. BRIGGS L, Fronek P, Quinn V, Wilde T, et al
    Perceptions of influenza and pneumococcal vaccine uptake by older persons in Australia.
    Vaccine. 2019 Jul 2. pii: S0264-410X(19)30856.
    >> Share

  566. DURALLIU A, Matejtschuk P, Dubey S, Koroma H, et al
    The influence of the closure format on the storage stability and moisture content of freeze-dried influenza antigen.
    Vaccine. 2019 Jul 2. pii: S0264-410X(19)30847.
    >> Share

    June 2019
  567. CORONEL J, Behrendt I, Burgin T, Anderlei T, et al
    Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.
    Vaccine. 2019 Jun 29. pii: S0264-410X(19)30764.
    >> Share

  568. VAN AALST R, Russo EM, Neupane N, Mahmud SM, et al
    Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease.
    Vaccine. 2019 Jun 28. pii: S0264-410X(19)30843.
    >> Share

  569. HAUSER MI, Muscatello DJ, Soh ACY, Dwyer DE, et al
    An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Vaccine. 2019 Jun 25. pii: S0264-410X(19)30801.
    >> Share

  570. DE OLIVEIRA BERNARDO C, Gonzalez-Chica DA, Chilver M, Stocks N, et al
    Influenza immunisation coverage from 2015 to 2017: A national study of adult patients from Australian general practice.
    Vaccine. 2019 Jun 25. pii: S0264-410X(19)30819.
    >> Share

  571. SINGH G, Zholobko O, Pillatzki A, Webb B, et al
    An amphiphilic invertible polymer as a delivery vehicle for a M2e-HA2-HA1 peptide vaccine against an Influenza A virus in pigs.
    Vaccine. 2019 Jun 21. pii: S0264-410X(19)30792.
    >> Share

  572. MANARA C, Brazzoli M, Piccioli D, Taccone M, et al
    Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines.
    Vaccine. 2019 Jun 18. pii: S0264-410X(19)30479.
    >> Share

  573. KWONG JC, Buchan SA, Chung H, Campitelli MA, et al
    Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort.
    Vaccine. 2019 Jun 17. pii: S0264-410X(19)30772.
    >> Share

  574. MURTI M, Otterstatter M, Orth A, Balshaw R, et al
    Measuring the impact of influenza vaccination on healthcare worker absenteeism in the context of a province-wide mandatory vaccinate-or-mask policy.
    Vaccine. 2019 Jun 13. pii: S0264-410X(19)30775.
    >> Share

  575. DEMARCUS L, Shoubaki L, Federinko S
    Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season.
    Vaccine. 2019 Jun 11. pii: S0264-410X(19)30763.
    >> Share

  576. NORDIN JD, Vazquez-Benitez G, Olsen A, Kuckler LC, et al
    Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma.
    Vaccine. 2019 Jun 10. pii: S0264-410X(19)30718.
    >> Share

  577. SHINJOH M, Sugaya N, Furuichi M, Araki E, et al
    Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013-18.
    Vaccine. 2019 Jun 8. pii: S0264-410X(19)30747.
    >> Share

  578. LIAO Q, Lam WWT, Wong CKH, Lam C, et al
    The relative effects of determinants on Chinese adults' decision for influenza vaccination choice: What is the effect of priming?
    Vaccine. 2019 Jun 8. pii: S0264-410X(19)30709.
    >> Share

  579. MURALIDHARAN A, Russell MS, Larocque L, Gravel C, et al
    Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice.
    Vaccine. 2019 Jun 8. pii: S0264-410X(19)30753.
    >> Share

  580. BORG K, Sutton K, Beasley M, Tull F, et al
    Reply to letter to the editor in response to the article "Communication-based interventions for increasing influenza vaccination rates among Aboriginal children: A randomised controlled trial".
    Vaccine. 2019;37:3382.
    >> Share

    May 2019
  581. NG Y, Nandar K, Chua LAV, Mak TM, et al
    Evaluating the effectiveness of the influenza vaccine during respiratory outbreaks in Singapore's long term care facilities, 2017.
    Vaccine. 2019 May 31. pii: S0264-410X(19)30388.
    >> Share

  582. KEITEL WA, Voronca DC, Atmar RL, Paust S, et al
    Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.
    Vaccine. 2019 May 31. pii: S0264-410X(19)30554.
    >> Share

  583. YAKUBOGULLARI N, Genc R, Coven F, Nalbantsoy A, et al
    Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS).
    Vaccine. 2019 May 30. pii: S0264-410X(19)30662.
    >> Share

  584. NICOLODI C, Groiss F, Kiselev O, Wolschek M, et al
    Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
    Vaccine. 2019 May 30. pii: S0264-410X(19)30627.
    >> Share

  585. BA-NGUZ A, Shah A, Bresee JS, Lafond KE, et al
    Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health's Partnership for influenza vaccine introduction.
    Vaccine. 2019 May 23. pii: S0264-410X(19)30670.
    >> Share

  586. LAESTADIUS A, Ingelman-Sundberg HM, Myrberg IH, Verme A, et al
    Altered proportions of circulating CXCR5+ helper T cells do not dampen influenza vaccine responses in children with rheumatic disease.
    Vaccine. 2019 May 21. pii: S0264-410X(19)30661.
    >> Share

  587. PEREZ-VILAR S, Wernecke M, Arya D, Lo AC, et al
    Surveillance for Guillain-Barre syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.
    Vaccine. 2019 May 20. pii: S0264-410X(19)30665.
    >> Share

  588. KOUL PA, Bali NK, Koul HP
    Influenza vaccination for Hajj for the next decade: A case for quadrivalent SH vaccine.
    Vaccine. 2019 May 16. pii: S0264-410X(19)30602.
    >> Share

  589. MANNING J, Dunne EM, Wang N, Pedersen JS, et al
    Effect of a pneumococcal whole cell vaccine on influenza A-induced pneumococcal otitis media in infant mice.
    Vaccine. 2019 May 15. pii: S0264-410X(19)30324.
    >> Share

  590. O'LEARY ST, Pyrzanowski J, Brewer SE, Sevick C, et al
    Effectiveness of a multimodal intervention to increase vaccination in obstetrics/gynecology settings.
    Vaccine. 2019 May 15. pii: S0264-410X(19)30658.
    >> Share

  591. KO EJ, Lee Y, Lee YT, Jung YJ, et al
    Flagellin-expressing virus-like particles exhibit adjuvant effects on promoting IgG isotype-switched long-lasting antibody induction and protection of influenza vaccines in CD4-deficient mice.
    Vaccine. 2019 May 14. pii: S0264-410X(19)30632.
    >> Share

  592. FELDMAN RA, Fuhr R, Smolenov I, Mick Ribeiro A, et al
    mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
    Vaccine. 2019 May 9. pii: S0264-410X(19)30562.
    >> Share

  593. AWAD S, Abdo N, Yusef D, Jawarneh A, et al
    Knowledge, attitudes and practices related to influenza illness and vaccination in children: Role of awareness campaigns in changing parents' attitudes toward influenza vaccination in Jordan.
    Vaccine. 2019 May 6. pii: S0264-410X(19)30571.
    >> Share

  594. TORCEL-PAGNON L, Bauchau V, Mahy P, Tin Tin Htar M, et al
    Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe.
    Vaccine. 2019 May 6. pii: S0264-410X(19)30561.
    >> Share

  595. BONOMO ME, Kim RY, Deem MW
    Modular epitope binding predicts influenza quasispecies dominance and vaccine effectiveness: Application to 2018/19 season.
    Vaccine. 2019 May 3. pii: S0264-410X(19)30417.
    >> Share

    April 2019
  596. DOYON-PLOURDE P, Fakih I, Tadount F, Fortin E, et al
    Impact of influenza vaccination on healthcare utilization - A systematic review.
    Vaccine. 2019 Apr 29. pii: S0264-410X(19)30525.
    >> Share

  597. BISSINGER T, Fritsch J, Mihut A, Wu Y, et al
    Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.
    Vaccine. 2019 Apr 29. pii: S0264-410X(19)30528.
    >> Share

  598. COHET C, van der Most R, Bauchau V, Bekkat-Berkani R, et al
    Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
    Vaccine. 2019 Apr 25. pii: S0264-410X(19)30522.
    >> Share

  599. XEUATVONGSA A, Mott JA, Khanthamaly V, Patthammavong C, et al
    Progress toward sustainable influenza vaccination in the Lao Peoples' Democratic Republic, 2012-2018.
    Vaccine. 2019 Apr 23. pii: S0264-410X(19)30511.
    >> Share

  600. HUERTAS-DIAZ MC, Phan S, Elson A, Nunez I, et al
    Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection.
    Vaccine. 2019 Apr 19. pii: S0264-410X(19)30506.
    >> Share

  601. GRANICHER G, Coronel J, Pralow A, Marichal-Gallardo P, et al
    Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
    Vaccine. 2019 Apr 17. pii: S0264-410X(19)30481.
    >> Share

  602. LEROUX-ROELS G, De Boever F, Maes C, Nguyen TL, et al
    Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Vaccine. 2019 Apr 12. pii: S0264-410X(19)30449.
    >> Share

  603. POLAND GA, Hall LL, Powell JA
    Effective and equitable influenza vaccine coverage in older and vulnerable adults: The need for evidence-based innovation and transformation.
    Vaccine. 2019;37:2167-2170.
    >> Share

  604. GORMAN DR, Bielecki K, Willocks LJ, Pollock KG, et al
    A qualitative study of vaccination behaviour amongst female Polish migrants in Edinburgh, Scotland.
    Vaccine. 2019 Apr 9. pii: S0264-410X(19)30422.
    >> Share

  605. GENTILE A, Paget J, Bellei N, Torres JP, et al
    Influenza in Latin America: A report from the Global Influenza Initiative (GII).
    Vaccine. 2019 Apr 8. pii: S0264-410X(19)30436.
    >> Share

  606. EL SAHLY HM, Atmar RL, Patel SM, Bellamy A, et al
    Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
    Vaccine. 2019 Apr 4. pii: S0264-410X(19)30420.
    >> Share

  607. PADILLA-QUIRARTE HO, Badillo-Godinez O, Gutierrez-Xicotencatl L, Acevedo-Betancur Y, et al
    Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
    Vaccine. 2019 Apr 4. pii: S0264-410X(19)30257.
    >> Share

  608. HAVERI A, Ikonen N, Kantele A, Anttila VJ, et al
    Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses.
    Vaccine. 2019 Apr 3. pii: S0264-410X(19)30427.
    >> Share

  609. REGAN AK, Fielding JE, Chilver MB, Carville KS, et al
    Intraseason decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: A test-negative design study and phylogenetic assessment.
    Vaccine. 2019 Apr 2. pii: S0264-410X(19)30222.
    >> Share

    March 2019
  610. SAWLWIN DC, Graves Jones A, Albano FR
    Modification of the vaccine manufacturing process improves the pyrogenicity profile of inactivated influenza vaccines in young children.
    Vaccine. 2019 Mar 29. pii: S0264-410X(19)30390.
    >> Share

  611. CASHMAN P, Moberley S, Chee K, Stephenson J, et al
    Participant centred safety surveillance of health care workers receiving influenza vaccination.
    Vaccine. 2019 Mar 28. pii: S0264-410X(19)30320.
    >> Share

  612. ARNOLD LD, Luong L, Rebmann T, Chang JJ, et al
    Racial disparities in U.S. maternal influenza vaccine uptake: Results from analysis of Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2012-2015.
    Vaccine. 2019 Mar 27. pii: S0264-410X(19)30208.
    >> Share

  613. ANDRES C, Peremiquel-Trillas P, Gimferrer L, Pinana M, et al
    Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012-2016) in Catalonia, Spain.
    Vaccine. 2019 Mar 27. pii: S0264-410X(19)30380.
    >> Share

  614. EVERETT HE, Aramouni M, Coward V, Ramsay A, et al
    Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.
    Vaccine. 2019 Mar 23. pii: S0264-410X(19)30316.
    >> Share

  615. TING-HUI-LIN, Chia MY, Lin CY, Yeh YQ, et al
    Improving immunogenicity of influenza virus H7N9 recombinant hemagglutinin for vaccine development.
    Vaccine. 2019;37:1897-1903.
    >> Share

  616. CRIADO MF, Bertran K, Lee DH, Killmaster L, et al
    Efficacy of novel recombinant fowlpox vaccine against recent Mexican H7N3 highly pathogenic avian influenza virus.
    Vaccine. 2019 Mar 15. pii: S0264-410X(19)30314.
    >> Share

  617. NORMAN DA, Danchin M, Van Buynder P, Moore HC, et al
    Caregiver's attitudes, beliefs, and experiences for influenza vaccination in Australian children with medical comorbidities.
    Vaccine. 2019 Mar 15. pii: S0264-410X(19)30315.
    >> Share

  618. SCHAFFER SJ, Rand CM, Humiston SG, Concannon C, et al
    Practical considerations in developing a successful school-located influenza vaccination (SLIV) program.
    Vaccine. 2019 Mar 13. pii: S0264-410X(19)30290.
    >> Share

  619. THORRINGTON D, van Leeuwen E, Ramsay M, Pebody R, et al
    Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Vaccine. 2019 Mar 11. pii: S0264-410X(19)30293.
    >> Share

  620. SEKIYA T, Mifsud EJ, Ohno M, Nomura N, et al
    Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.
    Vaccine. 2019 Mar 8. pii: S0264-410X(19)30264.
    >> Share

  621. PAN SC, Hsieh SM, Lin CF, Hsu YS, et al
    A randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of an intranasally administered trivalent inactivated influenza vaccine with adjuvant LTh(alphaK): A phase I study.
    Vaccine. 2019 Mar 2. pii: S0264-410X(19)30189.
    >> Share

  622. AINSLIE KEC, Haber M, Orenstein WA
    Bias of influenza vaccine effectiveness estimates from test-negative studies conducted during an influenza pandemic.
    Vaccine. 2019 Mar 1. pii: S0264-410X(19)30241.
    >> Share

    February 2019
  623. GIDUTHURI JG, Purohit V, Maire N, Kudale A, et al
    Influenza vaccination of pregnant women: Engaging clinicians to reduce missed opportunities for vaccination.
    Vaccine. 2019 Feb 28. pii: S0264-410X(19)30240.
    >> Share

  624. ZHANG D, Zhang Y, Wang Q, Lock J, et al
    The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18.
    Vaccine. 2019 Feb 28. pii: S0264-410X(19)30207.
    >> Share

  625. MEYER SB, Violette R, Aggarwal R, Simeoni M, et al
    Vaccine hesitancy and Web 2.0: Exploring how attitudes and beliefs about influenza vaccination are exchanged in online threaded user comments.
    Vaccine. 2019 Feb 27. pii: S0264-410X(19)30223.
    >> Share

  626. GETAHUN D, Fassett MJ, Peltier MR, Takhar HS, et al
    Association between seasonal influenza vaccination with pre- and postnatal outcomes.
    Vaccine. 2019 Feb 21. pii: S0264-410X(19)30214.
    >> Share

  627. WANG Z, Li Z, Su X, Qiao Y, et al
    Enhanced cross-lineage protection induced by recombinant H9N2 avian influenza virus inactivated vaccine.
    Vaccine. 2019 Feb 20. pii: S0264-410X(19)30206.
    >> Share

  628. WANG SH, Smith D, Cao Z, Chen J, et al
    Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
    Vaccine. 2019 Feb 19. pii: S0264-410X(19)30168.
    >> Share

  629. ABUBAKAR A, Melhem N, Malik M, Dbaibo G, et al
    Seasonal influenza vaccination policies in the Eastern Mediterranean Region: Current status and the way forward.
    Vaccine. 2019 Feb 19. pii: S0264-410X(19)30163.
    >> Share

  630. DUROUS L, Julien T, Padey B, Traversier A, et al
    SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30181.
    >> Share

  631. ZENG Y, Yuan Z, Yin J, Han Y, et al
    Factors affecting parental intention to vaccinate kindergarten children against influenza: A cross-sectional survey in China.
    Vaccine. 2019 Feb 12. pii: S0264-410X(19)30156.
    >> Share

  632. CHAE W, Kim P, Hwang BJ, Seong BL, et al
    Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.
    Vaccine. 2019 Feb 11. pii: S0264-410X(19)30153.
    >> Share

  633. HERRERA-RODRIGUEZ J, Signorazzi A, Holtrop M, de Vries-Idema J, et al
    Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
    Vaccine. 2019 Feb 11. pii: S0264-410X(19)30184.
    >> Share

  634. PEPIN S, Samson SI, Alvarez FP, Dupuy M, et al
    Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres.
    Vaccine. 2019 Feb 8. pii: S0264-410X(19)30144.
    >> Share

  635. YOUNG-XU Y, Snider JT, van Aalst R, Mahmud SM, et al
    Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.
    Vaccine. 2019 Feb 8. pii: S0264-410X(19)30148.
    >> Share

  636. HABER P, Moro PL, Ng C, Dores GM, et al
    Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Vaccine. 2019 Feb 7. pii: S0264-410X(19)30128.
    >> Share

  637. DOORNEKAMP L, de Jong W, Wagener MN, Goeijenbier M, et al
    Dutch healthcare professionals' opinion on vaccination and education to prevent infections in immunocompromised patients: A mixed-method study with recommendations for daily practice.
    Vaccine. 2019 Feb 7. pii: S0264-410X(19)30160.
    >> Share

  638. PETRIE JG, Martin ET, Truscon R, Johnson E, et al
    Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.
    Vaccine. 2019 Feb 6. pii: S0264-410X(19)30131.
    >> Share

  639. BORGEY F, Henry L, Lebeltel J, Lescure P, et al
    Effectiveness of an intervention campaign on influenza vaccination of professionals in nursing homes: A cluster-randomized controlled trial.
    Vaccine. 2019 Feb 6. pii: S0264-410X(19)30151.
    >> Share

  640. RAO S, Alishahi M, De Crescenzo L, Dempsey AF, et al
    A population-based study of maternal and infant factors influencing influenza vaccination among young children born in Colorado from 2008 to 2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30130.
    >> Share

    January 2019
  641. SHAPIRO JR, Hodgins B, Hendin HE, Patel A, et al
    Needle-free delivery of influenza vaccine using the Med-Jet(R) H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30103.
    >> Share

  642. QUINN SC, Jamison AM, An J, Hancock GR, et al
    Measuring vaccine hesitancy, confidence, trust and flu vaccine uptake: Results of a national survey of White and African American adults.
    Vaccine. 2019 Jan 29. pii: S0264-410X(19)30096.
    >> Share

  643. GHORBANI A, Ngunjiri JM, Xia M, Elaish M, et al
    Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
    Vaccine. 2019 Jan 25. pii: S0264-410X(19)30100.
    >> Share

  644. SAHIN Z, Neeleman R, Haines J, Kayser V, et al
    Preparation-free method can enable rapid surfactant screening during industrial processing of influenza vaccines.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30050.
    >> Share

  645. LU J, Luo M, Yee AZH, Sheldenkar A, et al
    Do superstitious beliefs affect influenza vaccine uptake through shaping health beliefs?
    Vaccine. 2019 Jan 22. pii: S0264-410X(19)30071.
    >> Share

  646. YUNG BS, Pugh H, Generotti AA, Phanhthilath N, et al
    Novel IFN-gamma ELISpot reveals robust T cell responses elicited after influenza nucleoprotein DNA vaccination in New Zealand White rabbits.
    Vaccine. 2019 Jan 17. pii: S0264-410X(19)30037.
    >> Share

  647. STRIJBOS E, Tannemaat MR, Alleman I, de Meel RHP, et al
    A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
    Vaccine. 2019 Jan 16. pii: S0264-410X(19)30038.
    >> Share

  648. BOCCALINI S, Tacconi FM, Lai PL, Bechini A, et al
    Appropriateness and preferential use of different seasonal influenza vaccines: A pilot study on the opinion of vaccinating physicians in Italy.
    Vaccine. 2019 Jan 14. pii: S0264-410X(19)30026.
    >> Share

  649. MOOIJ P, Grodeland G, Koopman G, Andersen TK, et al
    Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza.
    Vaccine. 2019 Jan 9. pii: S0264-410X(19)30005.
    >> Share

  650. MORAN A, Agaliotis M, Seale H
    The views of key stakeholders around mandatory influenza vaccination of hospital and aged care staff: Examining the current climate in Australia.
    Vaccine. 2019 Jan 6. pii: S0264-410X(18)31702.
    >> Share

  651. PRASERT K, Patumanond J, Praphasiri P, Siriluk S, et al
    Effectiveness of trivalent inactivated influenza vaccine among community-dwelling older adults in Thailand: A two-year prospective cohort study.
    Vaccine. 2019 Jan 4. pii: S0264-410X(19)30003.
    >> Share

  652. WEHBI NK, Wani RJ, Klepser DG, Murry J, et al
    Impact of implementing a technology platform in community pharmacies to increase adult immunizations rates.
    Vaccine. 2019;37:56-60.
    >> Share

    December 2018
  653. REGAN AK, Gibbs R, Bloomfield L, Effler PV, et al
    Estimating influenza vaccine effectiveness using data routinely available in electronic primary care records.
    Vaccine. 2018 Dec 29. pii: S0264-410X(18)31651.
    >> Share

  654. HURLEY LP, Allison MA, Kim L, O'Leary ST, et al
    Primary care physicians' perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults.
    Vaccine. 2018 Dec 28. pii: S0264-410X(18)31704.
    >> Share

  655. PEPIN S, Dupuy M, Borja-Tabora CFC, Montellano M, et al
    Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Vaccine. 2018 Dec 14. pii: S0264-410X(18)31637.
    >> Share

  656. MILLER PDE, de Silva TI, Leonard H, Anthias C, et al
    A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoieti
    Vaccine. 2018 Dec 13. pii: S0264-410X(18)31586.
    >> Share

  657. KIMOTO T, Kim H, Sakai S, Takahashi E, et al
    Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity i
    Vaccine. 2018 Dec 13. pii: S0264-410X(18)31647.
    >> Share

  658. OSHANSKY CM, Zhou J, Gao Y, Schweinle JE, et al
    Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
    Vaccine. 2018 Dec 12. pii: S0264-410X(18)31632.
    >> Share

  659. CATTAPAN A, Browne K, Halperin DM, Di Castri A, et al
    Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.
    Vaccine. 2018 Dec 6. pii: S0264-410X(18)31527.
    >> Share

  660. LEIDNER AJ, Murthy N, Chesson HW, Biggerstaff M, et al
    Cost-effectiveness of adult vaccinations: A systematic review.
    Vaccine. 2018 Dec 4. pii: S0264-410X(18)31581.
    >> Share

    November 2018
  661. BRESEE JS, McKinlay MA, Abramson J, Klugman KP, et al
    Global Funders Consortium for Universal Influenza Vaccine Development.
    Vaccine. 2018 Nov 29. pii: S0264-410X(18)31560.
    >> Share

  662. DAWA J, Chaves SS, Ba Nguz A, Kalani R, et al
    Developing a seasonal influenza vaccine recommendation in Kenya: Process and challenges faced by the National Immunization Technical Advisory Group (NITAG).
    Vaccine. 2018 Nov 27. pii: S0264-410X(18)31587.
    >> Share

  663. VAJO Z, Kalabay L, Vajo P, Balaton G, et al
    Licensing the first reduced, 6microg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial.
    Vaccine. 2018 Nov 26. pii: S0264-410X(18)31562.
    >> Share

  664. RIDDELL CA, Bhat N, Bont LJ, Dupont WD, et al
    Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
    Vaccine. 2018 Nov 22. pii: S0264-410X(18)31407.
    >> Share

  665. MCMORROW ML, Tempia S, Walaza S, Treurnicht FK, et al
    Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31573.
    >> Share

  666. STEAD M, Critchlow N, Eadie D, Sullivan F, et al
    Mandatory policies for influenza vaccination: Views of managers and healthcare workers in England.
    Vaccine. 2018 Nov 20. pii: S0264-410X(18)31556.
    >> Share

  667. TUCKERMAN J, Misan S, Salih S, Joseph Xavier B, et al
    Influenza vaccination: Uptake and associations in a cross-sectional study of children with special risk medical conditions.
    Vaccine. 2018 Nov 16. pii: S0264-410X(18)31299.
    >> Share

  668. BIELECKI K, Kirolos A, Willocks LJ, Pollock KG, et al
    Low uptake of nasal influenza vaccine in polish and other ethnic minority children in Edinburgh, Scotland.
    Vaccine. 2018 Nov 15. pii: S0264-410X(18)31552.
    >> Share

  669. YUE X, Black CL, Williams WW, Lu PJ, et al
    Influenza vaccination among adults living with persons at high-risk for complications from influenza during early 2016-17 influenza season.
    Vaccine. 2018 Nov 14. pii: S0264-410X(18)31499.
    >> Share

  670. WON SY, Hunt K, Guak H, Hasaj B, et al
    Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin.
    Vaccine. 2018 Nov 14. pii: S0264-410X(18)31496.
    >> Share

  671. KAHN KE, Santibanez TA, Zhai Y, Bridges CB, et al
    Association between patient reminders and influenza vaccination status among children.
    Vaccine. 2018 Nov 14. pii: S0264-410X(18)31395.
    >> Share

  672. SHANG M, Chung JR, Jackson ML, Jackson LA, et al
    Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016.
    Vaccine. 2018 Nov 9. pii: S0264-410X(18)31490.
    >> Share

  673. MUNOZ FM, Jackson LA, Swamy GK, Edwards KM, et al
    Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
    Vaccine. 2018 Nov 8. pii: S0264-410X(18)31475.
    >> Share

  674. WILCOX CR, Bottrell K, Paterson P, Schulz WS, et al
    Influenza and pertussis vaccination in pregnancy: Portrayal in online media articles and perceptions of pregnant women and healthcare professionals.
    Vaccine. 2018 Nov 3. pii: S0264-410X(18)31489.
    >> Share

    October 2018
  675. AHMED N, Quinn SC, Hancock GR, Freimuth VS, et al
    Social media use and influenza vaccine uptake among White and African American adults.
    Vaccine. 2018 Oct 30. pii: S0264-410X(18)31415.
    >> Share

  676. GILBERT BE, Patel N, Lu H, Liu Y, et al
    Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Vaccine. 2018 Oct 30. pii: S0264-410X(18)31458.
    >> Share

  677. KRAMER R, Duclos A, Lina B, Casalegno JS, et al
    Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France.
    Vaccine. 2018;36:6591-6593.
    >> Share

  678. BEKKAT-BERKANI R, Romano-Mazzotti L
    Understanding the unique characteristics of seasonal influenza illness to improve vaccine uptake in the US.
    Vaccine. 2018 Oct 23. pii: S0264-410X(18)31393.
    >> Share

  679. ZHAI Y, Santibanez TA, Kahn KE, Black CL, et al
    Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers.
    Vaccine. 2018 Oct 22. pii: S0264-410X(18)31405.
    >> Share

  680. DANCHIN MH, Costa-Pinto J, Attwell K, Willaby H, et al
    Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake.
    Vaccine. 2018;36:6473-6479.
    >> Share

  681. VAUGHN AR, Johnson ML
    Communicating and enhancing teachers' attitudes and understanding of influenza using refutational text.
    Vaccine. 2018 Oct 17. pii: S0264-410X(18)31406.
    >> Share

  682. WANG Q, Yue N, Zheng M, Wang D, et al
    Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis.
    Vaccine. 2018 Oct 16. pii: S0264-410X(18)31411.
    >> Share

  683. D'ALESSIO F, Koopman G, Houard S, Remarque EJ, et al
    Workshop report: Experimental animal models for universal influenza vaccines.
    Vaccine. 2018 Oct 16. pii: S0264-410X(18)31390.
    >> Share

  684. SANTIBANEZ TA, Kahn KE, Bridges CB
    Do parents prefer inactivated or live attenuated influenza vaccine for their children?
    Vaccine. 2018 Oct 16. pii: S0264-410X(18)31408.
    >> Share

  685. ZHANG L, Durr E, Galli JD, Cosmi S, et al
    Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
    Vaccine. 2018 Oct 16. pii: S0264-410X(18)31398.
    >> Share

  686. THANG HV, Huong VM, Victor JC, Van CB, et al
    Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam.
    Vaccine. 2018 Oct 15. pii: S0264-410X(18)31365.
    >> Share

  687. TOKARS JI, Rolfes MA, Foppa IM, Reed C, et al
    An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States.
    Vaccine. 2018 Oct 13. pii: S0264-410X(18)31392.
    >> Share

  688. YEOLEKAR LR, Ganguly M, Tyagi P, Ingle NB, et al
    Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Vaccine. 2018 Oct 12. pii: S0264-410X(18)31354.
    >> Share

  689. GERRETSEN HE, Capone S, Vitelli A, Reyes LS, et al
    Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection.
    Vaccine. 2018 Oct 11. pii: S0264-410X(18)31351.
    >> Share

  690. BARTSCH SM, Taitel MS, DePasse JV, Cox SN, et al
    Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic.
    Vaccine. 2018 Oct 5. pii: S0264-410X(18)31300.
    >> Share

  691. TSUZUKI S, Schwehm M, Eichner M
    Corrigendum to "Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination" [Vaccine 36 (2018) 624-630].
    Vaccine. 2018 Oct 3. pii: S0264-410X(18)31315.
    >> Share

  692. ROBISON SG, Thomas AR
    Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design.
    Vaccine. 2018 Oct 1. pii: S0264-410X(18)31319.
    >> Share

  693. GREEN CA, Sande CJ, de Lara C, Thompson AJ, et al
    Humoral and cellular immunity to RSV in infants, children and adults.
    Vaccine. 2018;36:6183-6190.
    >> Share

    September 2018
  694. BORG K, Sutton K, Beasley M, Tull F, et al
    Communication-based interventions for increasing influenza vaccination rates among Aboriginal children: A randomised controlled trial.
    Vaccine. 2018 Sep 29. pii: S0264-410X(18)31269.
    >> Share

  695. HAYASHI T, Lynch HE, Geyer S, Yoshida K, et al
    Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort.
    Vaccine. 2018 Sep 28. pii: S0264-410X(18)31323.
    >> Share

  696. MOMOSE H, Sasaki E, Kuramitsu M, Hamaguchi I, et al
    Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan.
    Vaccine. 2018 Sep 19. pii: S0264-410X(18)31270.
    >> Share

  697. BERTRAN K, Lee DH, Criado MF, Balzli CL, et al
    Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens.
    Vaccine. 2018 Sep 18. pii: S0264-410X(18)31264.
    >> Share

  698. DEDIEGO ML, Chiem K, Topham DJ
    Directed selection of amino acid changes in the influenza hemagglutinin and neuraminidase affecting protein antigenicity.
    Vaccine. 2018 Sep 14. pii: S0264-410X(18)31240.
    >> Share

  699. DIALLO A, Victor JC, Feser J, Ortiz JR, et al
    Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naive children in a randomized clinical trial in rural Senegal.
    Vaccine. 2018 Sep 14. pii: S0264-410X(18)31158.
    >> Share

  700. GAGNON A, Acosta E, Miller MS
    Reporting and evaluating influenza virus surveillance data: An argument for incidence by single year of age.
    Vaccine. 2018 Sep 12. pii: S0264-410X(18)31227.
    >> Share

  701. MCGRATH LJ, Layton JB, Krueger WS, Kshirsagar AV, et al
    High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013.
    Vaccine. 2018 Sep 5. pii: S0264-410X(18)31229.
    >> Share

  702. WESTRICK SC, Patterson BJ, Kader MS, Rashid S, et al
    National survey of pharmacy-based immunization services.
    Vaccine. 2018;36:5657-5664.
    >> Share

  703. MORGENSTERN K, Xie Y, Palladino G, Barr JR, et al
    Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination.
    Vaccine. 2018 Sep 4. pii: S0264-410X(18)31204.
    >> Share

  704. TAM YH, Ng TWY, Chu DKW, Fang VJ, et al
    The effectiveness of influenza vaccination against medically-attended illnesses in Hong Kong across three years with different degrees of vaccine match, 2014-17.
    Vaccine. 2018 Sep 3. pii: S0264-410X(18)31215.
    >> Share

  705. SOUZA CK, Rajao DS, Sandbulte MR, Lopes S, et al
    The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease.
    Vaccine. 2018 Sep 1. pii: S0264-410X(18)31212.
    >> Share

  706. MOMBELLI M, Rettby N, Perreau M, Pascual M, et al
    Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.
    Vaccine. 2018 Sep 1. pii: S0264-410X(18)31186.
    >> Share

    August 2018
  707. CHIU HT, Shen LJ, Chen YC, Lin JH, et al
    Effect of statin use on the risk of medically attended acute respiratory illness among influenza vaccinated elderly.
    Vaccine. 2018 Aug 30. pii: S0264-410X(18)31206.
    >> Share

  708. WHITAKER JA, von Itzstein MS, Poland GA
    Strategies to maximize influenza vaccine impact in older adults.
    Vaccine. 2018 Aug 25. pii: S0264-410X(18)31169.
    >> Share

  709. STONE K, Akpalu Y, Horney J
    Use of the Community Assessment for Public Health Response (CASPER) method to assess influenza vaccination and activity in Brazos County, Texas.
    Vaccine. 2018 Aug 24. pii: S0264-410X(18)31139.
    >> Share

  710. NEWALL AT, Chen C, Wood JG, Stockwell MS, et al
    Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States.
    Vaccine. 2018 Aug 23. pii: S0264-410X(18)31114.
    >> Share

  711. WEIBEL D, Sturkenboom M, Black S, de Ridder M, et al
    Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment.
    Vaccine. 2018 Aug 16. pii: S0264-410X(18)31115.
    >> Share

  712. PRICE GE, Lo CY, Misplon JA, Epstein SL, et al
    Reduction of influenza virus transmission from mice immunized against conserved viral antigens is influenced by route of immunization and choice of vaccine antigen.
    Vaccine. 2018;36.
    >> Share

  713. SHINJOH M, Sugaya N, Yamaguchi Y, Iibuchi N, et al
    Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season.
    Vaccine. 2018 Aug 6. pii: S0264-410X(18)31074.
    >> Share

  714. WU S, Pan Y, Zhang X, Zhang L, et al
    Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season.
    Vaccine. 2018 Aug 4. pii: S0264-410X(18)31097.
    >> Share

  715. YEUNG KHT, Tarrant M, Chan KCC, Tam WH, et al
    Increasing influenza vaccine uptake in children: A randomised controlled trial.
    Vaccine. 2018 Aug 2. pii: S0264-410X(18)31075.
    >> Share

  716. THOMPSON MG, Pierse N, Sue Huang Q, Prasad N, et al
    Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015.
    Vaccine. 2018 Aug 1. pii: S0264-410X(18)30997.
    >> Share

    July 2018
  717. ORTQVIST A, Brytting M, Leval A, Hergens MP, et al
    Impact of repeated influenza vaccinations in persons over 65years of age: A large population-based cohort study of severe influenza over six consecutive seasons, 2011/12-2016/17.
    Vaccine. 2018 Jul 31. pii: S0264-410X(18)31046.
    >> Share

  718. NOH JY, Choi WS, Song JY, Lee HS, et al
    Significant circulation of influenza B viruses mismatching the recommended vaccine-lineage in South Korea, 2007-2014.
    Vaccine. 2018 Jul 26. pii: S0264-410X(18)30987.
    >> Share

  719. STATLER VA, Albano FR, Airey J, Sawlwin DC, et al
    Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59months of age: A phase 3, randomized, noninferiority study.
    Vaccine. 2018 Jul 26. pii: S0264-410X(18)31005.
    >> Share

  720. FORD AJ, Alwan NA
    Use of social networking sites and women's decision to receive vaccinations during pregnancy: A cross-sectional study in the UK.
    Vaccine. 2018 Jul 25. pii: S0264-410X(18)30988.
    >> Share

  721. FERDMAN J, Palladino G, Liao HX, Moody MA, et al
    Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59(R)-adjuvanted pandemic 2009 H1N1 vaccine.
    Vaccine. 2018 Jul 25. pii: S0264-410X(18)30895.
    >> Share

  722. MACHADO A, Kislaya I, Santos AJ, Gaio V, et al
    Factors associated to repeated influenza vaccination in the Portuguese adults with chronic conditions.
    Vaccine. 2018 Jul 24. pii: S0264-410X(18)31010.
    >> Share

  723. KASPER AK, Pallotta AM, Kovacs CS, Spinner ML, et al
    Infectious diseases consult improves vaccination adherence in kidney transplant candidates.
    Vaccine. 2018 Jul 23. pii: S0264-410X(18)30899.
    >> Share

  724. MAKARKOV AI, Patel AR, Bainov V, Ward BJ, et al
    A novel serological assay for influenza based on DiD fluorescence dequenching that is free from observer bias and potentially automatable - A proof of concept study.
    Vaccine. 2018;36:4485-4493.
    >> Share

  725. ZHANG L, Pan Y, Hackert V, van der Hoek W, et al
    The 2015-2016 influenza epidemic in Beijing, China: Unlike elsewhere, circulation of influenza A(H3N2) with moderate vaccine effectiveness.
    Vaccine. 2018 Jul 14. pii: S0264-410X(18)30947.
    >> Share

  726. HATTA Y, Boltz D, Sarawar S, Kawaoka Y, et al
    Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
    Vaccine. 2018 Jul 12. pii: S0264-410X(18)30894.
    >> Share

  727. HARRISON N, Poeppl W, Miksch M, Machold K, et al
    Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.
    Vaccine. 2018 Jul 3. pii: S0264-410X(18)30906.
    >> Share

    June 2018
  728. BRADY RC, Jackson LA, Frey SE, Shane AL, et al
    Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.
    Vaccine. 2018 Jun 28. pii: S0264-410X(18)30864.
    >> Share

  729. PING X, Hu W, Xiong R, Zhang X, et al
    Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence.
    Vaccine. 2018 Jun 27. pii: S0264-410X(18)30889.
    >> Share

  730. SCHLAUDECKER EP, Ambroggio L, McNeal MM, Finkelman FD, et al
    Declining responsiveness to influenza vaccination with progression of human pregnancy.
    Vaccine. 2018 Jun 22. pii: S0264-410X(18)30796.
    >> Share

  731. SCHELTEMA NM, Kavelaars XM, Thorburn K, Hennus MP, et al
    Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy.
    Vaccine. 2018 Jun 22. pii: S0264-410X(18)30837.
    >> Share

  732. DAI X, Li N, Roller RJ
    Peroxiredoxin 1 protein interacts with influenza virus ribonucleoproteins and is required for efficient virus replication.
    Vaccine. 2018 Jun 16. pii: S0264-410X(18)30823.
    >> Share

  733. ORTIZ JR
    Implementation of maternal influenza immunization programs.
    Vaccine. 2018;36:3571.
    >> Share

  734. KOUL PA, Mir H
    The biggest barrier to influenza vaccination in pregnant females in India: Poor sensitization of the care providers.
    Vaccine. 2018;36:3569-3570.
    >> Share

  735. SHEN AK, Warnock R, Chu S, Kelman JA, et al
    Receipt of other routinely recommended vaccines relative to receipt of seasonal influenza vaccines: Trends from medicare administrative data, 2013-2015.
    Vaccine. 2018 Jun 13. pii: S0264-410X(18)30836.
    >> Share

  736. STRASSBERG ER, Power M, Schulkin J, Stark LM, et al
    Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy.
    Vaccine. 2018 Jun 12. pii: S0264-410X(18)30800.
    >> Share

  737. ENGELHARDT OG, Edge C, Dunleavy U, Guilfoyle K, et al
    Comparison of single radial immunodiffusion, SDS-PAGE and HPLC potency assays for inactivated influenza vaccines shows differences in ability to predict immunogenicity of haemagglutinin antigen.
    Vaccine. 2018 Jun 9. pii: S0264-410X(18)30742.
    >> Share

  738. JOYCE C, Scallan CD, Mateo R, Belshe RB, et al
    Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats.
    Vaccine. 2018 Jun 9. pii: S0264-410X(18)30789.
    >> Share

  739. VALKENBURG SA, Li OTW, Li A, Bull M, et al
    Protection by universal influenza vaccine is mediated by memory CD4 T cells.
    Vaccine. 2018 Jun 7. pii: S0264-410X(18)30818.
    >> Share

  740. FAN X, Su Q, Qiu F, Yi Y, et al
    Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Vaccine. 2018 Jun 4. pii: S0264-410X(18)30739.
    >> Share

  741. HENDRIKS J, Hutubessy RCW, Grohmann G, Torelli G, et al
    Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
    Vaccine. 2018 Jun 1. pii: S0264-410X(18)30766.
    >> Share

    May 2018
  742. GARRETSON TA, Petrie JG, Martin ET, Monto AS, et al
    Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.
    Vaccine. 2018 May 31. pii: S0264-410X(18)30752.
    >> Share

  743. FLEMING JA, Baltrons R, Rowley E, Quintanilla I, et al
    Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30762.
    >> Share

  744. ZHANG W, Sun H, Atiquzzaman M, Sou J, et al
    Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis.
    Vaccine. 2018 May 30. pii: S0264-410X(18)30743.
    >> Share

  745. ASTILL J, Alkie T, Yitbarek A, Abdelaziz KTA, et al
    Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Vaccine. 2018 May 28. pii: S0264-410X(18)30759.
    >> Share

  746. PUTRI WCWS, Muscatello DJ, Stockwell MS, Newall AT, et al
    Economic burden of seasonal influenza in the United States.
    Vaccine. 2018 May 22. pii: S0264-410X(18)30677.
    >> Share

  747. LOGAN J, Nederhoff D, Koch B, Griffith B, et al
    'What have you HEARD about the HERD?' Does education about local influenza vaccination coverage and herd immunity affect willingness to vaccinate?
    Vaccine. 2018 May 19. pii: S0264-410X(18)30657.
    >> Share

  748. YANG YT, Silverman RD
    Mandatory influenza vaccination and religious accommodation for healthcare workers: Lessons from recent legal challenges.
    Vaccine. 2018 May 19. pii: S0264-410X(18)30714.
    >> Share

  749. FERNANDO GJP, Hickling J, Jayashi Flores CM, Griffin P, et al
    Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch).
    Vaccine. 2018 May 17. pii: S0264-410X(18)30673.
    >> Share

  750. GRIEVES JL, Yin Z, Garcia-Sastre A, Mena I, et al
    A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.
    Vaccine. 2018 May 17. pii: S0264-410X(18)30609.
    >> Share

  751. JAIN S, George PJ, Deng W, Koussa J, et al
    The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4(+) T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.
    Vaccine. 2018 May 12. pii: S0264-410X(18)30636.
    >> Share

  752. KAHN KE, Santibanez TA, Zhai Y, Bridges CB, et al
    Association between provider recommendation and influenza vaccination status among children.
    Vaccine. 2018 May 12. pii: S0264-410X(18)30584.
    >> Share

  753. HARRISON SM, Wei MY, Lamerato LE, Petrie JG, et al
    Multimorbidity is associated with uptake of influenza vaccination.
    Vaccine. 2018 May 7. pii: S0264-410X(18)30628.
    >> Share

  754. ARRIOLA CS, Vasconez N, Bresee J, Ropero AM, et al
    "Knowledge, attitudes and practices about influenza vaccination among pregnant women and healthcare providers serving pregnant women in Managua, Nicaragua".
    Vaccine. 2018 May 7. pii: S0264-410X(18)30620.
    >> Share

  755. SEO J, Lim J
    Trends in influenza vaccination coverage rates in South Korea from 2005 to 2014: Effect of public health policies on vaccination behavior.
    Vaccine. 2018 May 5. pii: S0264-410X(18)30631.
    >> Share

  756. YEUNG KHT, Chan KCC, Chan PKS, Lam DSY, et al
    Influenza vaccine effectiveness in hospitalised Hong Kong children: Feasibility of estimates from routine surveillance data.
    Vaccine. 2018 May 5. pii: S0264-410X(18)30588.
    >> Share

  757. BARTOSZKO JJ, McNamara IF, Aras OAZ, Hylton DA, et al
    Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis.
    Vaccine. 2018 May 1. pii: S0264-410X(18)30546.
    >> Share

    April 2018
  758. BOEY L, Bral C, Roelants M, De Schryver A, et al
    Attitudes, believes, determinants and organisational barriers behind the low seasonal influenza vaccination uptake in healthcare workers - A cross-sectional survey.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30539.
    >> Share

  759. TESSIER E, Warburton F, Tsang C, Rafeeq S, et al
    Population-level factors predicting variation in influenza vaccine uptake among adults and young children in England, 2015/16 and 2016/17.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30581.
    >> Share

  760. REGAN AK, Gibbs RA, Effler PV
    An audit of the reliability of influenza vaccination and medical information extracted from eHealth records in general practice.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30583.
    >> Share

  761. SOMES MP, Turner RM, Dwyer LJ, Newall AT, et al
    Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis.
    Vaccine. 2018 Apr 28. pii: S0264-410X(18)30560.
    >> Share

  762. VAN DE WITTE S, Nauta J, Montomoli E, Weckx J, et al
    A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    Vaccine. 2018 Apr 27. pii: S0264-410X(18)30538.
    >> Share

  763. LI R, Xie R, Yang C, Rainey J, et al
    Identifying ways to increase seasonal influenza vaccine uptake among pregnant women in China: A qualitative investigation of pregnant women and their obstetricians.
    Vaccine. 2018 Apr 26. pii: S0264-410X(18)30557.
    >> Share

  764. HJERTNER B, Bengtsson T, Morein B, Paulie S, et al
    A novel adjuvant G3 induces both Th1 and Th2 related immune responses in mice after immunization with a trivalent inactivated split-virion influenza vaccine.
    Vaccine. 2018 Apr 26. pii: S0264-410X(18)30551.
    >> Share

  765. OHLROGGE AW, Suggs LS
    Flu vaccination communication in Europe: What does the government communicate and how?
    Vaccine. 2018 Apr 24. pii: S0264-410X(18)30525.
    >> Share

  766. KUCK LR, Byrne-Nash R, Gillis J, Bueter K, et al
    VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
    Vaccine. 2018 Apr 23. pii: S0264-410X(18)30545.
    >> Share

  767. DALE LP, White L, Mitchell M, Faulkner G, et al
    Smartphone app uses loyalty point incentives and push notifications to encourage influenza vaccine uptake.
    Vaccine. 2018 Apr 23. pii: S0264-410X(18)30487.
    >> Share

  768. VERHEES RAF, Dondorp W, Thijs C, Dinant GJ, et al
    Influenza vaccination in the elderly: Is a trial on mortality ethically acceptable?
    Vaccine. 2018 Apr 21. pii: S0264-410X(18)30510.
    >> Share

  769. SUZUKI M, Katsurada N, Le MN, Kaneko N, et al
    Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged >/=65years in Japan.
    Vaccine. 2018 Apr 20. pii: S0264-410X(18)30520.
    >> Share


  770. Response to three Letters to the Editor regarding: Donahue JG, et al. "Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12". Vaccine 35 (2017) 5314-5322.
    Vaccine. 2018;36:2231-2232.
    >> Share

  771. SARKAR I, Garg R, van Drunen Littel-van den Hurk S
    The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages.
    Vaccine. 2018;36:2326-2336.
    >> Share

  772. AULT KA, Riley LE
    Response to Donahue et al. 2017 in press article.
    Vaccine. 2018;36:2230.
    >> Share

  773. WEN Y, Palladino G, Xie Y, Ferrari A, et al
    Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
    Vaccine. 2018 Apr 18. pii: S0264-410X(18)30490.
    >> Share

  774. HOSCHLER K, Southern J, Thompson C, Warburton F, et al
    Responses to live attenuated influenza vaccine in children vaccinated previously with Pandemrix (ASO3B adjuvanted pandemic A/H1N1pdm09).
    Vaccine. 2018 Apr 18. pii: S0264-410X(18)30486.
    >> Share

  775. SZILAGYI PG, Schaffer S, Rand CM, Goldstein NPN, et al
    Impact of elementary school-located influenza vaccinations: A stepped wedge trial across a community.
    Vaccine. 2018 Apr 17. pii: S0264-410X(18)30403.
    >> Share

  776. SHIBATA N, Kimura S, Hoshino T, Takeuchi M, et al
    Effectiveness of influenza vaccination for children in Japan: Four-year observational study using a large-scale claims database.
    Vaccine. 2018 Apr 13. pii: S0264-410X(18)30460.
    >> Share

  777. BISSET KA, Paterson P
    Strategies for increasing uptake of vaccination in pregnancy in high-income countries: A systematic review.
    Vaccine. 2018 Apr 13. pii: S0264-410X(18)30482.
    >> Share

  778. HOFFMANN A, Dumke C, Hanschmann KO, Wicker S, et al
    Local thermal reaction after influenza vaccination: Quantification by infrared imaging and biometric considerations.
    Vaccine. 2018 Apr 10. pii: S0264-410X(18)30467.
    >> Share

  779. LAPUENTE D, Ruzsics Z, Thirion C, Tenbusch M, et al
    Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.
    Vaccine. 2018 Apr 5. pii: S0264-410X(18)30262.
    >> Share

  780. DABAGHIAN M, Latifi AM, Tebianian M, NajmiNejad H, et al
    Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
    Vaccine. 2018 Apr 4. pii: S0264-410X(18)30259.
    >> Share

  781. CONLIN AMS, Bukowinski AT, Levine JA, Khodr ZG, et al
    A follow-up comparative safety analysis of pandemic H1N1 vaccination during pregnancy and risk of infant birth defects among U.S. military mothers.
    Vaccine. 2018 Apr 3. pii: S0264-410X(18)30417.
    >> Share

    March 2018
  782. ESPOSITO S, Franco E, Gavazzi G, de Miguel AG, et al
    The public health value of vaccination for seniors in Europe.
    Vaccine. 2018 Mar 31. pii: S0264-410X(18)30409.
    >> Share

  783. WENDLANDT R, Cowling BJ, Chen Y, Havers F, et al
    Knowledge, attitudes and practices related to the influenza virus and vaccine among older adults in Eastern China.
    Vaccine. 2018 Mar 29. pii: S0264-410X(18)30408.
    >> Share

  784. KASSIANOS G, Kuchar E, Nitsch-Osuch A, Kyncl J, et al
    Motors of influenza vaccination uptake and vaccination advocacy in healthcare workers: A comparative study in six European countries.
    Vaccine. 2018 Mar 28. pii: S0264-410X(18)30205.
    >> Share

  785. MUFLIHAH H, Florido M, Lin LCW, Xia Y, et al
    Sequential pulmonary immunization with heterologous recombinant influenza A virus tuberculosis vaccines protects against murine M. tuberculosis infection.
    Vaccine. 2018 Mar 27. pii: S0264-410X(18)30382.
    >> Share

  786. CITRON MP, Patel M, Purcell M, Lin SA, et al
    A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates.
    Vaccine. 2018 Mar 26. pii: S0264-410X(18)30320.
    >> Share

  787. KRETZSCHMAR E, Muckenfuss H, Pfleiderer M
    Official batch control of influenza vaccines: Is it still useful?
    Vaccine. 2018 Mar 23. pii: S0264-410X(18)30275.
    >> Share

  788. WANG Y, Chen L, Yu J, Pang Y, et al
    The effectiveness of influenza vaccination among nursery school children in China during the 2016/17 influenza season.
    Vaccine. 2018 Mar 23. pii: S0264-410X(18)30384.
    >> Share

  789. ALFELALI M, Barasheed O, Badahdah AM, Bokhary H, et al
    Influenza vaccination among Saudi Hajj pilgrims: Revealing the uptake and vaccination barriers.
    Vaccine. 2018 Mar 16. pii: S0264-410X(18)30343.
    >> Share

  790. SOEDJATMIKO S, Medise BE, Gunardi H, Sekartini R, et al
    Immunogenicity and safety of a Trivalent Influenza HA vaccine in Indonesian infants and children.
    Vaccine. 2018 Mar 15. pii: S0264-410X(18)30324.
    >> Share

  791. LINDSAY BJ, Bonar MM, Costas-Cancelas IN, Hunt K, et al
    Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Vaccine. 2018 Mar 14. pii: S0264-410X(18)30316.
    >> Share

  792. NICHOLS MK, Andrew MK, Hatchette TF, Ambrose A, et al
    Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious
    Vaccine. 2018 Mar 13. pii: S0264-410X(18)30292.
    >> Share

  793. KESHTKAR-JAHROMI M, Ouyang M, Keshtkarjahromi M, Almed S, et al
    Effect of influenza vaccine on tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in older adults.
    Vaccine. 2018 Mar 13. pii: S0264-410X(17)31609.
    >> Share

  794. TETE SM, Jul-Larsen A, Rostami S, Lunde THF, et al
    Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Vaccine. 2018 Mar 13. pii: S0264-410X(18)30196.
    >> Share

  795. RIKIN S, Jia H, Vargas CY, Castellanos de Belliard Y, et al
    Assessment of temporally-related acute respiratory illness following influenza vaccination.
    Vaccine. 2018 Mar 7. pii: S0264-410X(18)30315.
    >> Share

  796. SUNDARAM N, Duckett K, Yung CF, Thoon KC, et al
    "I wouldn't really believe statistics" - Challenges with influenza vaccine acceptance among healthcare workers in Singapore.
    Vaccine. 2018 Mar 5. pii: S0264-410X(18)30312.
    >> Share

  797. SURTEES TC, Teh BW, Slavin MA, Worth LJ, et al
    Factors contributing to declination of annual influenza vaccination by healthcare workers caring for cancer patients: An Australian experience.
    Vaccine. 2018 Mar 1. pii: S0264-410X(18)30297.
    >> Share

  798. CZAKO R, Vogel L, Sutton T, Matsuoka Y, et al
    H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.
    Vaccine. 2018 Mar 1. pii: S0264-410X(18)30248.
    >> Share

    February 2018
  799. ARMITAGE EP, Camara J, Bah S, Forster AS, et al
    Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia.
    Vaccine. 2018 Feb 23. pii: S0264-410X(18)30211.
    >> Share

  800. WESTCOTT MM, Clemens EA, Holbrook BC, King SB, et al
    The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.
    Vaccine. 2018;36:1174-1182.
    >> Share

  801. KING JP, McLean HQ, Meece JK, Levine MZ, et al
    Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
    Vaccine. 2018;36:1214-1219.
    >> Share

  802. WHITE KM, Ayllon J, Mena I, Potenski A, et al
    Influenza B virus reverse genetic backbones with improved growth properties in the EB66(R) cell line as basis for vaccine seed virus generation.
    Vaccine. 2018;36:1146-1153.
    >> Share

  803. IBANEZ LI, Caldevilla CA, Paredes Rojas Y, Mattion N, et al
    Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains.
    Vaccine. 2018 Feb 15. pii: S0264-410X(18)30193.
    >> Share

  804. SYCHEVA AL, Pogorelyy MV, Komech EA, Minervina AA, et al
    Quantitative profiling reveals minor changes of T cell receptor repertoire in response to subunit inactivated influenza vaccine.
    Vaccine. 2018 Feb 15. pii: S0264-410X(18)30201.
    >> Share

  805. DJAGBARE MD, Yu L, Parupudi A, Sun J, et al
    Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Vaccine. 2018 Feb 15. pii: S0264-410X(18)30115.
    >> Share

  806. MAGIRI R, Lai K, Chaffey A, Zhou Y, et al
    Intradermal immunization with inactivated swine influenza virus and adjuvant polydi(sodium carboxylatoethylphenoxy)phosphazene (PCEP) induced humoral and cell-mediated immunity and reduced lung viral titres in pigs.
    Vaccine. 2018 Feb 14. pii: S0264-410X(18)30200.
    >> Share

  807. BAYER L, Fertey J, Ulbert S, Grunwald T, et al
    Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30188.
    >> Share

  808. PANDO R, Sharabi S, Mandelboim M
    Exceptional influenza morbidity in summer season of 2017 in Israel may predict the vaccine efficiency in the coming winter.
    Vaccine. 2018 Feb 8. pii: S0264-410X(18)30158.
    >> Share

  809. DE BEKKER-GROB EW, Veldwijk J, Jonker M, Donkers B, et al
    The impact of vaccination and patient characteristics on influenza vaccination uptake of elderly people: A discrete choice experiment.
    Vaccine. 2018 Feb 6. pii: S0264-410X(18)30103.
    >> Share

  810. RUSSELL K, Chung JR, Monto AS, Martin ET, et al
    Influenza vaccine effectiveness in older adults compared with younger adults over five seasons.
    Vaccine. 2018 Feb 2. pii: S0264-410X(18)30094.
    >> Share

    January 2018
  811. VEKEMANS J, Moorthy V, Giersing B, Friede M, et al
    Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.
    Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364.
    >> Share

  812. KAPLAN BS, Souza CK, Gauger PC, Stauft CB, et al
    Vaccination of pigs with a codon-pair bias de-optimized live attenuated influenza vaccine protects from homologous challenge.
    Vaccine. 2018 Jan 20. pii: S0264-410X(18)30061.
    >> Share

  813. DE BOER PT, Kelso JK, Halder N, Nguyen TP, et al
    The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    Vaccine. 2018 Jan 17. pii: S0264-410X(17)31836.
    >> Share

  814. MORIMOTO N, Takeishi K
    Change in the efficacy of influenza vaccination after repeated inoculation under antigenic mismatch: A systematic review and meta-analysis.
    Vaccine. 2018 Jan 17. pii: S0264-410X(18)30057.
    >> Share